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ABSTRACT 
 
Schizosaccharomyces pombe Glucose/cAMP Signaling Requires the Hsp90/Git10 
Chaperone and the Git7 Co-chaperone 
 
 
By Manal Alaamery 
 
Advisor: Charles Hoffman 
 
 
The fission yeast Schizosaccharomyces pombe senses environmental glucose through a 
cAMP-signaling pathway.  Elevated cAMP levels activate protein kinase A (PKA) to 
inhibit transcription of genes involved in sexual development and gluconeogenesis, 
including the fbp1+ gene, which encodes fructose-1,6-bisphosphatase. Glucose-mediated 
activation of PKA requires the function of nine git genes (git=glucose insensitive 
transcription), encoding adenylate cyclase, the PKA catalytic subunit and seven 
“upstream” proteins required for glucose-triggered adenylate cyclase activation. This 
thesis describes the cloning and characterization of the git10+ gene, which is identical to 
swo1+ and encodes the S. pombe Hsp90 chaperone protein. This discovery is consistent 
with the previous identification of the Git7 protein as a member of the Sgt1 Hsp90 
co-chaperone family. Glucose repression of fbp1+ transcription is impaired by both 
hsp90- and git7-  mutant alleles, as well as by chemical inhibition of Hsp90 activity and 
temperature stress. Unlike the swo1- and git7- ts mutant alleles, the git10-201 allele and 
git7-93 allele support cell growth at 37º and show no cytokinesis defect, while severely 
reducing glucose repression of an fbp1-lacZ reporter, suggesting a separation-of-function 
defect. A physical interaction between Git7 and Hsp90 in S. pombe was also 
detected and findings in this thesis suggest their involvement in the initial assembly of 
the cAMP complex.  
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INTRODUCTION 
 
 
 
 
 
 2 
INTRODUCTION 
 
1.1. Signal Transduction 
Signal transduction allows a cell to interact with its environment and it is how the cell 
converts a specific external or internal signal to a chain of cellular reactions. This results 
in a particular action or response that is crucial to the cell’s existence. The initiation of a 
signal often starts with an external stimulus first interacting with a receptor on the surface 
of the cell. This receptor can then initiate the production of a second messenger, which 
will subsequently amplify and transmit the signal to targets. As a result of the signaling, a 
negative or positive response results in these target proteins being either inhibited or 
activated. The signal sometimes results in an alteration in gene expression, which is 
ultimately responsible for different but very specific outcomes.   
 
For instance, the binding of certain hormones to specific receptors on the surface of a cell 
triggers the production of cyclic AMP (cAMP) within the cell (Coppe and Steer, 1978). 
Cyclic AMP is a second messenger, which will initiate the internal signaling cascade. 
Other second messengers include cyclic GMP, InsP3 and calcium (CLAPHAM 1995; 
COPPE and STEER 1978; DIVECHA and IRVINE 1995; PFISTER 1989). In general, these 
second messengers serve to amplify the external signal and bring about the final effect of 
the signal. 
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1.2. Cyclic AMP Pathway  
Cyclic AMP is a small molecule that has a very important role in both prokaryotes and 
eukaryotes. It is synthesized from adenosine triphosphate (ATP) by an enzyme called 
adenylate cyclase and is degraded by another enzyme called cAMP phosphdiesterase. 
 
The concentration of cAMP in the cell is critical for different cellular processes.  The 
strength of the transduced signal is controlled by cAMP concentrations, which in turn is 
determined by a balance in the production and the degradation of cAMP. It is very 
important to have the right amount of cAMP at the right time in the right place; any 
change in this process can result in aberrant cell behavior. For example impaired cAMP 
signaling contributes to the pathophysiology of cardiovascular, neurological, metabolic 
and inflammatory disorders (CAI et al. 2001; MOORE and WILLOUGHBY 1995; 
MOVSESIAN and BRISTOW 2005). Recently, direct monitoring of rapid subcellular cAMP 
dynamics has been utilized to gain a better understanding of disease mechanisms 
(WILLOUGHBY and COOPER 2008). 
 
A significant role of cAMP is to activate protein kinase A (PKA) which will then affect 
the transcription of specific genes (BEEBE 1994). Amazingly, cAMP regulation is an 
ancient mechanism that is highly conserved from bacteria to humans (DAS et al. 2007; 
KAMENETSKY et al. 2006).  
 4 
However, our understanding of the diverse biological effects of cAMP regulation is still 
in its infancy. Uncovering how cAMP signal translates into a specific gene expression 
change is crucial to enable the control of defective regulation that may contribute to 
disease (SANDS and PALMER 2008). Since cAMP signaling is present in simpler single 
cell organisms, these organisms serve as convenient models for studying cAMP signaling 
pathways. 
 
1.3. Cyclic AMP signaling in Schizosaccharomyces pombe 
Glucose signaling pathways regulate gene expression in both prokaryotic and eukaryotic 
cells, and have been well studied in a variety of model organisms. The fission yeast 
Schizosaccharomyces pombe monitors glucose to regulate a wide range of biological 
processes such as sexual development and metabolism. Unlike Saccharomyces 
cerevisiae, which senses glucose through a number of signaling pathways, glucose 
detection in Schizosaccharomyces pombe is primarily through a cAMP-signaling 
pathway (HOFFMAN 2005a; HOFFMAN 2005b).  
 
In S. cerevisiae and S. pombe, glucose-cAMP signaling is very similar with only a few 
key differences. In general, both have a G-protein receptor that activates a G-protein, 
which in turn activates adenylate cyclase (HOFFMAN 2005a; IVEY and HOFFMAN 2005). 
In S. cerevisiae, glucose signaling also involves Ras proteins (COLOMBO et al. 1998; 
FUKUI et al. 1986; MBONYI et al. 1988; MINTZER and FIELD 1994). In contrast, the S. 
 5 
pombe Ras homolog plays no role in adenylate cyclase activation (FUKUI et al. 1986; 
HOFFMAN and WINSTON 1991).  
 
Our lab has focused on the transcriptional regulation of the glucose-repressed fbp1+ gene, 
which encodes the gluconeogenic enzyme fructose-1,6-bisphosphatase in S. pombe 
(VASSAROTTI and FRIESEN 1985). Previously, we identified mutations in genes that 
confer constitutive fbp1+ transcription (HOFFMAN and WINSTON 1990). These glucose 
insensitive transcription (git) genes encode the components of a PKA pathway (HOFFMAN 
2005b), which acts antagonistically to a stress-activated MAPK (SAPK) pathway 
required for fbp1+ transcription (STETTLER et al. 1996; STIEFEL et al. 2004). 
 
The S. pombe cAMP signaling genes have been identified by using genetic screens to 
find mutants defective in glucose repression of transcription of the gene fbp1 (HOFFMAN 
2005b; HOFFMAN and WINSTON 1991). One of the imperative genes was identified to be 
git2+/cyr1+ which encodes adenylate cyclase (HOFFMAN and WINSTON 1991). The S. 
pombe cyr1/git2 adenylate cyclase gene was cloned by different groups by hybridization 
using the S. cerevisiae CYR1 gene. On the contrary to S. cerevisiae, S. pombe adenylate 
cyclase is not essential and not regulated by Ras protein (FUKUI et al. 1986; HOFFMAN 
and WINSTON 1991; MAEDA et al. 1990; YAMAWAKI-KATAOKA et al. 1989; YOUNG et al. 
1989). The function of adenylate cyclase is to produce the second messenger cAMP from 
ATP to activate PKA, whose catalytic subunit is encoded by the pka1+/git6+ gene (JIN et 
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al. 1995; MAEDA et al. 1990; YU et al. 1994) and whose regulatory subunit is encoded by 
the cgs1+ gene (DEVOTI et al. 1991).  
 
The git6/pka1 was cloned by its ability to suppress the dominant-negative mutation of the 
S. cerevisiae RAS2 gene (YU et al. 1994). The loss of the catalytic activity of Pka1p 
mimics a starvation signal allowing the cell to conjugate and sporulate even in the 
presence of abundant nutrients. On the other hand, mutations in genes that elevate PKA 
activity inhibit cell conjugation. This led to the identification of cgs1 which encodes the 
regulatory subunit of PKA and cgs2 that encodes phosphodiesterase (DeVoti et al. 1991), 
as mutations in these genes suppress the lethal haploid meiosis conferred by a pat1- 
mutation.  
 
Seven additional git genes are required for adenylate cyclase activation and form at least 
two functionally distinct groups. Four genes encode the Git3 G protein-coupled receptor 
(WELTON and HOFFMAN 2000) and its cognate heterotrimeric G protein composed of the 
Gpa2 Gα (ISSHIKI et al. 1992; NOCERO et al. 1994), the Git5 Gβ (LANDRY et al. 2000), 
and the Git11 Gγ (LANDRY and HOFFMAN 2001). Overexpression of Gpa2 suppresses the 
defect in fbp1 transcriptional repression caused by git3 or git5 mutations. These findings 
suggest that Gpa2 functions downstream from Git3 and Git5 (LANDRY et al. 2000) 
(Figure1). In addition, using a two-hybrid assay we found that Git3 interacts with Gpa2 
and this interaction was facilitated by the Git5 Gβ (D.A. Kelly and C.S. Hoffman, 
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unpublished results (HOFFMAN 2005b). The Git3 GPCR and Git5-Git11 Gβγ dimer are 
required for Gpa2 Gα activation, and can be bypassed by mutations that activate Gpa2 
(WELTON and HOFFMAN 2000), which directly binds and activates adenylate cyclase 
(IVEY and HOFFMAN 2005).  
 
Interestingly, unlike the other git genes, mutations in git7, git10, and git1 cannot be 
suppressed by an activated allele of gpa2 (WELTON and HOFFMAN 2000). Therefore, they 
either function independently from Gpa2 to activate adenylate cyclase or are required for 
Gpa2-mediated activation of adenylate cyclase by stabilizing or assembling a functional 
complex (Figure1). Git1 contains a C2 domain, which in some proteins binds 
phospholipids, and two munc domains (MHD1 and MHD2) that might also bind 
phospholipids (KOCH et al. 2000). Genetics and biochemical studies indicate that git1 is 
required for the activation of adenylate cyclase (BYRNE and HOFFMAN 1993). In addition 
co-immunoprecipitation experiments have detected physical interactions between Git1 
and Git2/ adenylate cyclase (KAO et al. 2006). 
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Figure 1. Schizosaccharomyces pombe cAMP signaling pathway  
The Git3 protein detects glucose and transfers the signal to the heterotrimeric G proteins, which will in turn 
activate Git2 adenylate cyclase, which will produce cAMP. Three other proteins Git7, Git10, and the Git1 
are also required for the activation of Git2. Elevation of cAMP levels results in activation of PKA. This 
action will affect the transcription of specific genes like fbp1 in Schizosaccharomyces pombe. 
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Figure 1. 
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Git7 is a member of the Sgt1 protein family, whose Saccharomyces cerevisiae ortholog 
SGT1 was originally identified as a multicopy suppressor of skp1 mutation. SGT1 has 
been implicated in adenylate cyclase function (DUBACQ et al. 2002). It is also essential 
and appeared to be important for septation and maintaining cell wall integrity (DUBACQ 
et al. 2002; SCHADICK et al. 2002) and kinetochore assembly (KITAGAWA et al. 1999).  
 
The goal of this thesis project was to identify and characterize git10, the one remaining 
git gene that plays an important role in fbp1 repression. Through a mapping approach, I 
discovered that git10 encodes Hsp90, a heat shock protein that is a member of the 90 kD 
protein family found in many eukaryotes, including the budding yeast S. cerevisiae, 
plants, and mammals (BARDWELL and CRAIG 1987; LINDQUIST and CRAIG 1988b; 
SPENCE and GEORGOPOULOS 1989). The git10/hsp90 gene was previously identified as 
swo1, a gene that when mutated suppresses the mitotic effect of overexpression of wee1 
kinase, which negatively regulates mitotic entry (ALIGUE et al. 1994). 
 
1.4. Hsp90 function and signaling  
Hsp90 is one of the most abundant cellular proteins under normal conditions and is 
highly expressed in response to different kinds of stress including heat, osmotic stress 
(SATHIYAA et al. 2001; SPEES et al. 2002), and toxic stresses (SNYDER et al. 2001; 
WIEGANT et al. 1998). Hsp90 is an essential molecular chaperone, a molecule which is 
greatly conserved from bacteria to mammals (BARDWELL and CRAIG 1987; LINDQUIST 
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and CRAIG 1988a; SPENCE and GEORGOPOULOS 1989). The high sequence homology and 
conserved structure of Hsp90 suggest that its function might also be preserved across 
species. Using the molecular biology toolkit (MBT), a protein workshop software 
(MORELAND et al. 2005) I was able to show how remarkably closely the structure of 
human and Saccharomyces cerevisiae Hsp90 resemble each other due to high Hsp90 
conservation (Figure 2). 
 
Another Hsp90 isoform that has been reported is Hsp90N, which is involved in the 
cellular transformation process (GRAMMATIKAKIS et al. 2002). In addition Hsp90 
paralogs includes Grp94, a glucose regulated protein and the mitochondrial Trap1/Hsp75 
(CSERMELY et al. 1998; NEMOTO et al. 1996). In S. cerevisiae there are two isoforms 
Hsp82, a heat shock induced chaperone, and Hsc82 a constitutively expressed protein 
(ALIGUE et al. 1994; BORKOVICH et al. 1989). Both in S. cerevisiae and in S. pombe, 
Hsp90 is essential for cell viability.  
 
Hsp90’s function is highly complex. To understand this complexity, several groups have 
tried to uncover the Hsp90 network in yeast and mammalian systems using proteomic 
and genomic approaches (FALSONE et al. 2005; ZHAO et al. 2005).  
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Figure 2. Comparison of the structures of human and yeast Hsp90 
Comparison of the structures of human and yeast Hsp90 to show how closely they resemble each other due 
to high Hsp90 conservation. (A) The N-terminal domain of human Hsp90 (1yet) binding to Geldanamycin 
(GA). (B) The N-terminal domain of Saccharomyces cerevisiae Hsp90 (1a4h) binding to Geldanamycin 
(GA). Images were created using MBT protein workshop (MORELAND et al. 2005) available on protein data 
bank (PDB) website. Human crystal structure data was obtained from (STEBBINS et al. 1997) and yeast 
structural data from (PRODROMOU et al. 1997). 
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Figure 2. 
A. 
 
 
B. 
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It is an unusual chaperone in that most of its identified substrates are signal transduction 
proteins (PEARL and PRODROMOU 2000; POWERS and WORKMAN 2006; ZHANG and 
BURROWS 2004). The Hsp90 protein networks suggest that Hsp90 plays a central role 
affecting multiple pathways and cellular processes, such as signaling of steroid hormone 
receptors and protein kinases (NOLLEN and MORIMOTO 2002; RICHTER and BUCHNER 
2001), membrane trafficking (BIJLMAKERS and MARSH 2000; FAN et al. 2006; SAKISAKA 
et al. 2002) and the cytoskeletal network (PAI et al. 2001); (KORCSMAROS et al. 2007) 
(Figure 3). Therefore, the number of client proteins identified for Hsp90 has been 
increasing gradually.  
 
Hsp90 regulates cellular functions in different ways. Hsp90 can help in folding newly 
synthesized proteins and also facilitate the maturation of many proteins to a stable 
confirmation (CSERMELY et al. 2007; KORCSMAROS et al. 2007; MILLSON et al. 2005; 
ZHAO et al. 2005; ZHAO and HOURY 2007). In addition, Hsp90 function in complex with 
various co-chaperones that regulate its function. The different co-chaperones can direct 
Hsp90 to different sets of substrates/targets (ZHAO and HOURY 2005). Therefore, Hsp90 
is a crucial element for a target protein to function in different signaling pathways. 
However, the structural flexibility that is needed for these substrates to carry out diverse 
cellular functions may render them less stable and make them more susceptible to 
damage if Hsp90 was compromised (YOUNG et al. 2001).  
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Figure 3. Hsp90 complex network 
Hsp90 is involved with protein-protein interactions, the cytoskeletal network, and membrane trafficking 
(KORCSMAROS et al. 2007). Signaling through Hsp90 links these pathways to each other. See Picard list 
http://www.picard.ch/downloads/Hsp90interactors.pdf. 
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Figure 3. 
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As a result, a compromised Hsp90 will result in the destabilization of client proteins and 
induce their degradation. 
 
1.4. Hsp90 role in evolution, cancer, and immunity  
In fruit fly and in plants Hsp90 demonstrates an important role in evolution by masking 
mutations. It acts as a buffering device to maintain the wild type phenotype. The Hsp90 
impaired by either mutations or by pharmacological inhibitors led to developmental 
abnormalities. The Lindquist lab established that these developmental abnormalities 
phenotypes were due to reduced Hsp90 function. They also showed that elevated 
temperature could produce Hsp90-dependent phenotypes. The reason for that remarkable 
effect may be that Hsp90 has a crucial role in stabilizing proteins that are involved in a 
intricate signaling pathway (MITCHELL-OLDS and KNIGHT 2002; RUTHERFORD 2003; 
RUTHERFORD and LINDQUIST 1998). 
 
On the other hand, Hsp90 inhibition is sometimes beneficial. Recent research has 
revealed a distinctive medically important role of Hsp90 in cancer (CHIOSIS G et al.  
2004; GOETZ et al. 2003; MALONEY A and P. 2002). Hsp90 is overexpressed in cancer 
cells and required for the stability and function of signaling proteins that promote cancer 
cell growth (ISAACS et al. 2003; NATHAN and LINDQUIST. 1995; NECKERS 2007; PRATT 
and TOFT. 1997; WHITESELL and LINDQUIST 2005). In a murine model system, Hsp90 
was concentrated in tumor tissue while being unaltered in other tissues (BANERJI et al. 
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2005; EISEMAN et al. 2005; NECKERS 2007; VILENCHIK et al. 2004; XU et al. 2003). 
Therefore, Hsp90 is a potential anticancer drug target. For example, geldanamycin is a 
specific Hsp90 inhibitor that blocks the ATP binding site of Hsp90, thus impairing its 
chaperone activity, which will limit a variety of cell signaling pathways and cell growth 
(OBERMANN et al. 1998; SCHNEIDER et al. 1996).  
 
Hsp90 also plays a central role in innate immunity in higher eukaryotes. In plants, it has 
been shown that Hsp90, SGT1, and RAR1 together regulate the stability of R proteins, a 
family of proteins that is important in disease resistance (AZEVEDO et al. 2002; BOTER et 
al. 2007; LIU et al. 2004; TAKAHASHI et al. 2003; THAO et al. 2007). Recently, it has also 
been shown that Hsp90 plays an important role in the immune response in mammalians. 
This process involves an Hsp90 co-chaperone Sgt1, together they activate the immune 
response by inducing the Nod-like receptor proteins (NLR) to form an inflammasome 
complex (MAYOR et al. 2007). Since the immune response networks in plants and 
mammals share some general components, Hsp90-Sgt1 signaling might be a conserved 
mechanism that regulates the immune response and ensures disease resistance (Figure 4). 
 
1.5. Hsp90 structure and the Chaperone Cycle  
Hsp90 possesses three domains: an N-terminal ATP-binding domain, a central regulatory 
domain involved in client protein-binding, and a C-terminal dimerization domain (Figure 
5A) (PEARL and PRODROMOU 2006). 
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Figure 4. Hsp90, co-chaperones and clients act on different cellular processes 
Hsp90 and its co-chaperones act on a wide range of client proteins kinases, transcription factors, and others 
to control different cellular processes (JACKSON et al. 2004; KORCSMAROS et al. 2007).  
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Figure 4. 
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Emerging evidence suggests the importance of the middle domain of Hsp90 and sheds 
light on its role in the activation of the N-terminal ATP-binding domain. In S. cerevisiae, 
it has been shown that Hsp90 middle domain interacts with Aha1, a co-chaperone that 
stimulates ATP hydrolysis and enhances the efficiency of its client protein activity either 
indirectly or directly (FONTANA J et al. 2002; MEYER et al. 2003; SATO et al. 2000). A 
recent report showed that the middle domain could also play a role in discriminating 
between different types of client proteins (HAWLE et al. 2006). 
 
The N-terminus had been identified by structural studies and biochemical studies to be 
the ATP binding site of Hsp90 and can be also blocked by Geldanamycin (GA), a 
specific Hsp90 inhibitor (BUCHNER 1999; STEBBINS et al. 1997). On the other hand, the 
C-terminus of Hsp90 also has an important role since truncations of this region resulted 
in unviable yeast cells (LOUVION et al. 1996; MINAMI et al. 1994) and also abolished 
ATP hydrolysis (PRODROMOU et al. 2000). These results imply that the N-terminal 
domain of Hsp90, which is important for ATP hydrolysis (RICHTER et al. 2002), is 
enhanced by the C-terminal dimerization (TERASAWA et al. 2005). Conformational 
changes of Hsp90 when bound to ADP or ATP is important to the function of the 
chaperone cycle which includes the transition process between the open and the closed 
structure (Figure 5B) (CSERMELY et al. 1993; GRENERT et al. 1997; SULLIVAN et al. 
1997).  
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Figure 5. Hsp90 structure and Hsp90  ATPase cycle 
(A) Hsp90 contains three domains: (N) the N-terminal (ATP) binding domain, (M) the middle or -protein 
binding domain, (C) the C-terminus or dimerization domain. 
(B) The inactive form of Hsp90 is the open/relaxed structure. ATP binding activates Hsp90 and induces 
conformational changes, creating a closed structure. Adapted from (PRODROMOU et al. 2000; TERASAWA et 
al. 2005) 
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Figure 5. 
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The ADP-bound Hsp90 form, which is the open structure, is capable of capturing the 
client proteins (Figure 6A). ATP binding will induce conformation changes, resulting in a 
closed state (Figure 6B) that will result in client protein encapsulation (RICHTER and 
BUCHNER 2006). There is also evidence that a wide range of co-chaperones play an 
important role in the loading (Figure 6A) and releasing (Figure 6C) mechanisms of 
Hsp90 in a client-specific manner (BUCHNER 1999; KELLERMAYER and CSERMELY 1995; 
PEARL and PRODROMOU 2006). 
 
Natural inhibitors, geldanamycin produced from Streptomyces hygroscopicus (DEBOER et 
al. 1970) and the antifungal antibitotic radicicol produced by Humicola fuscoatra (SOGA 
et al. 2003) bind to the ATP conserved pocket resulting in compromised ATPase activity 
(PRODROMOU et al. 1997; SCHULTE et al. 1999; STEBBINS et al. 1997). Blocking the ATP 
site locks Hsp90 in the ADP confirmation thereby inducing client degradation (Figure 
6D).  
 
1.6. Hsp90 functions in the context of Sgt1 structure  
Sgt1 is found in humans (LEE et al. 2004; STEENSGAARD et al. 2004), Arabidopsis 
thaliana (AZEVEDO et al. 2002), Saccharomyces cerevisiae (KITAGAWA et al. 1999), and 
recently in S. pombe, designated git7 (SCHADICK et al. 2002). Sgt1p contains three 
important domains (Figure 7).  
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Figure 6. Hsp90 Clamp mechanism 
(A) Hsp90 in the open state can capture the client protein. (B) ATP binding induces Hsp90 conformational 
changes resulting in the closed state. The closed structure facilitates client activation and/or assembly with 
another protein. (C) Some co-chaperones will accelerate the ATPase reaction, which results in client 
disassociations. (D) Geldanamycin (GA) blocks the ATP binding site, which will result in client 
destabilization and degradation (BAGATELL and WHITESELL 2004; MEYER et al. 2003; PEARL and 
PRODROMOU 2006; RICHTER and BUCHNER 2006). 
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Figure 6. 
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Figure 7. Schematic of Sgt1 protein structure   
Schematic of Sgt1 protein structure showing the three domains: TRP, CS, and SGS   and the binding site of  
Hsp90. In addition it shows some phenotypes associated with Sgt1 mutants in humans (LEE et al. 2004) and 
Saccharomyces cerevisiae (BANSAL et al. 2004; DUBACQ et al. 2002) compared to its ortholog Git7 in 
Schizosaccharomyces pombe (SCHADICK et al. 2002). Geldanamycin is a drug that inhibits Hsp90 function. 
TRP: tetratricopeptide repeat domain. CS: CHORD domain. SGS: Sgt1 specific domain. 
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Figure 7. 
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The N-terminus contains a tetratricopeptide repeat domain (TRP) (LAMB et al. 1995) 
which is conserved from humans to yeast (KORDES et al. 1998). Proteins that contain the 
TRP motif were found to be involved in protein folding, protein–protein interactions, and 
cell cycle and transcription regulation (BLATCH and LASSLE 1999). 
 
Mutations in this domain alter normal cellular processes due to disruption of protein 
interactions. This domain was found to interact transiently with Hsp90 in S. cerevisiae 
and A. thaliana (BANSAL et al. 2004; TAKAHASHI et al. 2003) an interaction that is 
essential for the formation of the Centromere Binding Factor 3 (CBF3), and the 
kinetochore complex (LINGELBACH and KAPLAN 2004). 
 
Sgt1 works as a linker to connect Hsp90 to Skp1 which results in CBF3 complex 
formation by activating Ctf13. Therefore Sgt1 may function as a co-chaperone that 
recruits specific clients to Hsp90 (CATLETT and KAPLAN 2006). In plants the Hsp90 
interaction with the TRP domain of Sgt1 was found to be important in disease resistance 
(TAKAHASHI et al. 2003). In S. pombe, git7-27 and the git7-235 alleles, which contain 
single missense mutations in the region encoding the amino terminus of Git7 
demonstrates defective phenotype in cAMP signaling, cell wall integrity and septation 
(SCHADICK et al. 2002). 
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The middle domain of Sgt1, referred to as the CHORD (CS) domain, is also conserved 
among species. Proteins that contain this region were found to interact with Hsp90 
(AZEVEDO et al. 2002; DUBACQ et al. 2002). In contrast to S. cerevisiae, human Sgt1 
binds Hsp90 through the CS domain (LEE et al. 2004). Structural analysis using NMR 
and mutational analyses of the CS domain of Sgt1 in Arabidopsis thaliana showed that 
the CHORD II domain of RAR1 and the N-terminus domain of HSP90 interact with 
opposite faces of the CS domain of Sgt1. The Sgt1 function in Rx resistance is 
specifically dependent on its interaction with Hsp90, demonstrating that the role of Sgt1 
may be to recruit chaperone activity to multi protein complexes (BOTER et al. 2007).  
 
The C-terminus of Sgt1 contains the SGS domain, which stands for Sgt1 specific domain. 
This domain is the most evolutionarily conserved region within the protein across 
different species; therefore it might carry a conserved function (AZEVEDO et al. 2002). 
Mutations in this region showed defects in SCF (Skp1p/Cdc53p–Cullin–F-box) 
machinery and the cAMP pathway. These mutants were also sensitive to geldanamycin, 
which indicates Hsp90 involvement in these processes. For example in S. cerevisiae, the 
sgt1-5 allele, which is a mutation in the C-terminus was defective in SCF ubiquitination, 
in adenylate cyclase activity and was sensitive to geldanamycin (BANSAL et al. 2004; 
KITAGAWA et al. 1999).  
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In S. cerevisiae Sgt1 physically interacts with the yeast adenylate cyclase Cyr1p/Cdc35p 
(DUBACQ et al. 2002). However, Sgt1 involvement in cAMP signaling was observed but 
SGT1/Git7 and Cyr1/Git2 interactions were not found in S. pombe (Wang, unpublished 
data). Interestingly cells expressing git7-93, which has duplication in the C-terminal 
coding region, display a defect in cAMP pathway and not in any other functions 
associated with other git7 mutant alleles. Thus, this region is specifically involved in 
cAMP pathway (SCHADICK et al. 2002).   
 
1.7. Focus of research  
Prior to this study, genes that were responsible for mutants defective in glucose 
repression of fbp1 transcription were all cloned with the exception of git10. The initial 
aim is to clone and characterize the git10 gene. I will describe here the cloning process 
and provide evidence that it encodes a heat shock protein Hsp90 that plays an important 
role in cAMP pathway (ALAAMERY and HOFFMAN 2008).  
 
I have determined for the first time that the induction of fbp1 transcription during heat 
stress acts through Hsp90, suggesting a novel link between temperature sensing and 
nutrient sensing through a PKA pathway in S. pombe.  
 
Before this study, Git7 a member of the Sgt1 protein family had been shown to be 
important for septation, cell wall integrity and proper cAMP signaling in S. pombe 
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(SCHADICK et al. 2002). I demonstrated that Git7’s function in maintaining cell wall 
integrity requires functional Hsp90. Furthermore; I showed that Swo1/Hsp90 and Git7 
proteins interact suggesting their presence in the same complex. These findings establish 
a connection between Hsp90 and Git7 that have never been previously revealed in S. 
pombe. In other systems, the interaction between Git7 and Hsp90 is important in the 
transient assembly of protein complexes.  
 
Finally, I analyzed the effect of compromising Hsp90 on key players of the cAMP 
pathway. This analysis indicates that Hsp90 is involved in assembling the cAMP-
signaling complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
 
 
 
 
 
 
 
 
 
 
CHAPTER TWO 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 34 
MATERIALS AND METHODS 
 
 
2.1. MATERIALS 
2.1.1. Growth Medium  
Yeast was grown and maintained using several types of media. Yeast extract agar (YEA) 
and yeast extract liquid (YEL) are the standard media supplemented with 0.2% casamino 
acids (GUTZ et al. 1974). Defined medium EMM (MP Biochemicals) was supplemented 
with required nutrients at 75 mg/L, except for L-leucine, which was at 150 mg/L. 
Sensitivity to 5-fluoro-orotic acid (5FOA) was determined on SC solid medium 
containing 0.4 g/L 5-fluoro-orotic acid 5FOA and 8% glucose as previously described 
(HOFFMAN and WINSTON 1990). LB medium (1% tryptone, 0.5% yeast extract, 1% NaCl) 
was used to grow E. coli. 
 
2.1.2. Yeast  
Table 1 lists the yeast strains used in this study. Most of the strains in this thesis carried 
the fbp1::ura4+ and ura4::fbp1-lacZ reporters (Figure 8). Both are translational fusions 
integrated at the fbp1+ and ura4+ loci, respectively, as described by Hoffman and 
Winston (HOFFMAN and WINSTON 1990). Strains were grown at 30°C unless otherwise 
indicated. 
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Table 1. Strain list  
Strain   Genotype          
FWP17 mat2-102    ura4-294     lys1-131  
FWP72 h-   fbp1::ura4+   ura4::fbp1-lacZ leu1-32  
FWP87 h+   fbp1::ura4+   ura4::fbp1-lacZ leu1-32  
CHP27    h+   fbp1::ura4+    ura4::fbp1-lacZ     leu1-32   ade6-M210  his7-366   git7-27 
CHP465  h-    fbp1::ura4+    ura4::fbp1-lacZ     leu1-32   ade6-M210 git7-235 
CHP567  h+   fbp1::ura4+    ura4::fbp1-lacZ     leu1-32   ade6-M210   git10-201   
CHP573  h-    fbp1::ura4+   ura4::fbp1-lacZ     leu1-32   ade6-M210   his7-366   git10-201 
CHP894  h-   fbp1::ura4+    ura4::fbp1-lacZ     leu1-32   lys1-131  cdc1-P13   git10-201 
CHP981  h-   fbp1::ura4+    ura4::fbp1-lacZ     leu1-32   ade6-M210   swo1-26  
CHP979  h+   fbp1::ura4+    ura4::fbp1-lacZ     leu1-32  ade6-M210  his7-366   swo1-26  
CHP989  h+   fbp1::ura4+    ura4::fbp1-lacZ     leu1-32    swo1-21  
PR164     h- ura4-D18     leu1-32   swo1-21 
PR165     h- ura4-D18     leu1-32   swo1-25 
CHP362 h90  leu1-32       ade6-M210   lys1-131 
CHP558 h90 fbp1::ura4+   leu1-32  ade6-M216  git2-1::LEU2    
CHP486 h90 leu1-32  lys1-131 git5-1::his7 
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CHP483 h90    ura4::fbp1-lacZ     leu1-32   ade6-M216 
MAP1    h90          fbp1::ura4+    ura4::fbp1-lacZ     leu1-32      git10-201 
MAP10    -         fbp1::ura4+    ura4::fbp1-lacZ  git2-Myc::kan git1-V5::leu+  git7-93 
MAP12    -    fbp1::ura4+    ura4::fbp1-lacZ  git2-Myc::kan git1-V5::leu+ 
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Figure 8. Two translational fusions and their associated phenotypes 
 (A) Two constructed under the fbp1 promoter, used for selecting mutations that are defective in repression 
of fbp1 transcription. (B) Strains carrying fbp1-ura4 and fbp1-lacZ fusions are Ura-, 5FOA-resistant, and 
express little β-galactosidase activity when grown under repressing conditions (8% glucose).  
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Figure 8.  
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B. 
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2.1.3. Bacteria  
ElectroTen-Blue or XL1-Blue electroporation-competent cells (Stratagene, La Jolla, CA) 
or TOP10 chemical-competent cells were used to amplify plasmids (Invitrogen, San 
Diego). Bacterial transformants were selected on (100 mg/L) ampicillin resistance LB 
plates. 
 
2.1.4. Enzymes  
Restriction endonuclease enzymes, ligation enzymes, and their buffers were purchased 
from New England Biolabs (NEB, Ipswich, MA). Protocols for digestion reactions were 
performed using NEB catalog. NEB cutter software was also used to visualize the 
restriction digestion patterns (VINCZE et al. 2003). AccuPrime Taq DNA polymerase was 
purchased from Invitrogen (Carlsbad,CA). PfuTurbo DNA polymerase was purchased 
from Stratagene (La Jolla, CA). Lastly, the Failsafe PCR kit was purchased from 
(Epicentre Technologies, Madison, WI). 
 
2.2. METHODS  
2.2.1. Strain mating and tetrad dissection  
Stains were patched on YEA solid media prior to mating. The freshly streaked strains 
were then mated on malt-extract agar (MEA) for 24 to 48 h at 30˚C. In the case of 
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homothallic stains, they were pregrown at 37˚C before mating. Asci formed on MEA 
were transferred using a dissection needle to YEA 3% glucose rich plate. Selected 
zygotic asci were then incubated at 37˚C for at least 2 h to facilitate the breakage of the 
cell wall and the release of spores. Tetrads were then needle dissected on the plate and 
moved away from each other to ease the scoring process. Plates were then incubated at 30 
˚C for 3 days and then scored.  
 
2.2.2. β-galactosidase assays of fbp1-lacZ expression  
Cells were cultured for 18 h under repressing conditions (8% glucose) in yeast extract at 
the indicated temperatures (YEL) or PM for transformants. Subcultures were grown to 
exponential phase 1x107 cells/mL. Soluble protein extracts were prepared by glass bead 
in breaking buffer  (0.1 M Tris pH 8, 20% glycerol, 1mM DTT) and PSMF (40mM). The 
assay was performed using Z buffer according to in current molecular biology protocol. 
Ortho-nitrophenyl-β-galactoside (ONPG) was used to start the reaction and Na2CO3 (1 
M) solution was used to stop the reaction when a yellow color appeared. Samples were 
read at OD420. Total
 soluble protein was measured by BCA assay (Pierce Chemical Co) to 
calculate β-galactosidase-specific activity (NOCERO et al. 1994).  
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2.2.3. X-Gal Filter Lift  
This assay was used to confirm the present of the lacZ reporter in the strain. Strains for 
testing were patched on YEA or solid selective medium and grown for 24 to 48 h before 
testing. Cells were replica-plated directly onto a 0.2µm BioTrace NT nitrocellulose 
membrane filter (Pall Life Sciences, East Hills, NY). The filter that absorbed the cells 
was then submerged into liquid nitrogen for 60 s to lyse the cells. Afterwards, the filter 
was moved from liquid nitrogen and allowed to thaw for 2 min. The filter with the cells 
was laid on a blotting paper saturated with 2.5 mL of Z buffer mixed with 150 µl of 5-
bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal) (20 mg/mL). The cells were 
incubated at 30˚C for 15 min or until a color developed. Stains that carried lacZ reporter 
turned blue.  
 
2.2.4. PCR walking  
Polymerase chain reactions (PCR) were performed using the high Fidelity PCR kit for 
enzyme Pfu according to the manufacturer’s instruction. PCR walking method was 
preformed on cosmid SPAC926 to cover the region where git10+ gene was mapped to by 
using the following primers: 
[Git10-1F (5’CTGGAAACCTGACGCGGGTA3’) and Git10-1R (5’CTTTGCAACGTA 
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CTTCTACTCGC3’)], [Git10-2F(5’CCGTACTTCTTACGGCG CTC3’) and Git10-2R( 
5’ GCTGAAAAGCATGCTCCCGA 3’)], [Git10-3F (5’CCGTACTTCTTACGGCG CT 
C3’) and Git10-3R(5’CAAATTTTATACGGCCCGC3’)], [Git10-4F (5’GAATTCCAAA 
ACGCGGGC3’) and Git10-4R (5’TAAGCCAAATTCCGAACGG3’)], [Git10-5F (5’AA 
AATTTCTGACCGCTCGG3’) and Git10-5R (5’GCGTTTGCTGTACGAGAGGG 3’)],  
[Git10-6F(5’CTTCCATAACGTCTTCTACACGC3’) and Git10-6R (5’TCATCAACGT 
ATACGTTCGGG3’)], [Git10-7F (5’TGAGCCATAATAGCCCGAACG3’) and Git10-
7R (5’ACAAATGCAATGCGCCTAAC3’)], [Git10-8F (5’AACTGCAGTGATCGGAC 
GGG3’) and Git10-8R (5’GGGTTACATTTACGCTCTACGC3’)], [Git10-9F (5’ATGG 
CTAGAAAAGGGACGGC3’) and Git10-9R (5’GCAAACCCTTCACGAGTGTC 3’)]. 
 
2.2.5. DNA sequencing 
Mutant alleles of hsp90+ gene (swo1-21, swo1-25, swo1-26, and git10-201) were PCR 
amplified from S. pombe strains and the PCR products were directly sequenced using 
custom oligonucleotides (Integrated DNA Technologies). DNA sequencing was 
performed using the CEQ DTCS-Quick Start kit (Beckman Coulter).  
 
2.2.6. Cloning and Plasmid Constructions 
The S. pombe genomic DNA insert from cosmid SPAC926 was amplified by PCR using 
custom oligonucleotides that divided the insert into nine segments (see Figure 9) and 
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cloned using pNMT41 TOPO cloning vector (Invitrogen) according to the manufacturer’s 
instructions.  
 
2.2.7. Epitope-tagging of Hsp90 
hsp90-for (5’ATGTCGAACACAGAAACTTTCAAG3’) and hsp90-revTAG (5’ 
ATCGACTTCCTCCATCTTGCTC3’) were used in a PCR reaction on wild type S. 
pombe genomic DNA to amplify the hsp90+ ORF. The resultant PCR product, lacking 
the hsp90+ STOP codon, was cloned into the TOPO cloning vector pNMT41 vector 
(Invitrogen) creating plasmid pMAR3, which expresses Hsp90 with a C-terminal V5 
(SOUTHERN et al. 1991) tag followed by a hexahistidine tag (Hsp90-V5his6).  
 
2.2.8. Protein extraction for Western blot analysis 
Strains were grown in YEL 3% glucose to log phase 1x107 cells/mL. Protein extracts 
were prepared on ice by TCA precipitation as described by Volland. (VOLLAND et al. 
1994) 
 
2.2.9. Co-immunoprecipitation  
S. pombe strains MAP12, MAP10, CHP456, and CHP27  were grown to exponential 
phase and broken in lysis buffer (50 mM Tris-HCl [pH 7.5], 0.2% Triton X-100, 300 mM 
NaCl, protease inhibitor) by grinding in liquid nitrogen. A total of 800 µl of cell lysate 
was incubated with 2.5 µl of α-Sgt1 (donated by the Ken Kaplan lab) for 1 h at 4°C on a 
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rotator. 50 µl  of Protein G Sepharose 4 Fast Flow (Amersham Pharmacia) was added in a 
1:1 ratio with lysis buffer and incubated on a rotator for 2 h at 4°C. Precipitated immune 
complexes were isolated by microcentrifugation for 20 seconds. The pellets were washed 
six times with lysis buffer. Pellets were resuspended in 30 µl of Laemmli buffer and 
heated for 3 min at 95°C. Beads were pelleted by centrifugation for 20 seconds, and the 
supernatants were removed for analysis. 
 
2.2.10. Western and immunoblotting  
Protein extracts were separated by 4%-15% SDS-PAGE gradient gel (Biorad; Hercules, 
CA) and transferred to a polyvinylidene difluoride membrane (PVDF) (Millipore; 
Temecula, CA). Membranes were blocked for 3 h at room temperature in 5% nonfat milk 
powder dissolved in Tris-saline-Tween-20 buffer (TBST). The PVDF membrane was 
washed three times with 1 X (TBST). Immunodetection of V5-tagged and Myc–tagged 
proteins were performed using monoclonal mouse α-V5 (Invitrogen) and monoclonal 
mouse α-myc (Santa Cruz Biotechnology). Then, peroxidase-labeled goat α-mouse IgG 
secondary antibody (Kirkegaard & Perry Laboratories) was used as secondary antibodies 
to recognize mouse primary antibodies. Actin protein was detected using mouse 
polyclonal IgG (JLA20) against actin and peroxidase-conjugated goat α-mouse IgG was 
used as a secondary antibody. Gpa2 was detected using α-S. pombe Gpa2 antibody while 
peroxidase-conjugated goat α-rabbit IgG served as a secondary antibody. The Hsp90 was 
detected by using α-Hsp90 (K41220) primary mouse antibody. Then, peroxidase-labeled 
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goat α-mouse IgG was used as secondary antibodies to recognize mouse primary 
antibodies. Samples were visualized using LumiGLO Enhanced chemiluminescence 
(Kirkegaard & Perry Laboratories; KPL) following manufacturer’s directions. 
 
2.2.11. Tandem Affinity Purification (TAP) 
Strains CHP993 (git7-235), and CHP998 (git10-201) both carrying a TAP-tagged 
adenylate cyclase were grown overnight in 1 L of YEL 8% glucose to log phase. Cells 
were then collected by filtration and ground with the filter in liquid nitrogen and glass 
beads. The lysate was transferred to a 50 mL falcon tube and centrifuged in a table 
centrifuge for 5 minutes at 3500 rpm. Then the supernatant was transferred to a Nalgene 
tube and centrifuged for 1 h using the 70Ti rotor at 38,000 rpm.  Then, 800 µl of IgG 
/sepharose in NP-40 buffer (1:1) was added to the clear lysate and incubated for 2 h at 4° 
C on a rotating platform. Then, the lysate the beads were poured into a Biorad Poly 
Chromatography column.The beads were washed with 30 mL IPP150 buffer and by TEV 
cleavage buffer. Then, the TEV was added and the column was closed at the top and 
bottom and incubated for 2 h at 16°C. After 2 h of incubation with TEV, the eluate was 
drained to a new column with 1 mL of TEV CB. CBB buffer was then added to the TEV 
supernatant with 6 µl of 1M CaCl2 and 300 µl of calmodulin resin and incubated for 1 h 
at 4°C. Beads were then washed twice with CBB 0.1% NP-40 and once with CBB 0.02% 
NP-40. Samples were then eluated in 1 mL CEB and 0.02% NP-40 and split in half. Both 
halves were TCA precipitated and washed first with cold acetone and (0.05 N) HCl and 
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then with only acetone. Supernant was removed and pellets were dried using speed 
vacuum. The first half was analyzed by running the samples in SDS-PAGE and then 
silver-stained using a Biorad kit. The other half was analyzed using sent for mass 
spectrometry analysis.  
 
2.2.12. Spot Plating assay  
Spot tests on hsp90+, swo1-26, swo1-21, and git10-201 strains were preformed at 25ºC, 
28ºC, 30ºC, and 37ºC. Strains FWP72 (wild type), CHP567 (git10-201), CHP989 (swo1-
21), CHP979 (swo1-26), were cultured to 1 x 107 cells/mL in YEL liquid medium. Cells 
then were washed with YEL medium and adjusted to 2 x 107 cells/mL along with five 10-
fold serial dilutions. Five microliters of each culture were spotted on a YEA plate and grown 
for 3 days at the indicated temperature before photographing. 
 
2.2.13. Starvation-independent mating test  
To test if homothallic git10-201 cells can conjugate and sporulate in rich medium, 
homothallic (h90) strains CHP362 (git10+), CHP558 (git2Δ), CHP486 (git5Δ), and MAP1 
(git10-201) were grown to exponential phase in PM liquid medium (8% glucose) at 37°C (to 
inhibit conjugation), diluted to 106 cells/mL in PM liquid medium in the presence or absence 
of 5 mM cAMP, and incubated overnight at 30°C without shaking. Cells were then observed 
under the microscope and images were captured. 
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2.2.14. Glucose uptake assay  
Glucose uptake was determined using quantitative glucose (GO) assay kit (Sigma, MO). By 
using glucose oxidase, the glucose in medium was oxidized to gluconic acid and hydrogen 
peroxide, which then reacted with o-dianisidine in the presence of peroxidase to form a 
colored product. Sulfuric acid was then added to form a more stable product. The 
absorbance of the color was measured at 540 nm. The glucose level in YEL was measured 
using the supernatant. The pellet from the same sample was also used for β-galactosidase 
analysis. 
 
2.2.15. Cyclic AMP extraction  
Cells were collected by air vacuum into micropore glass filters (Fisher). Filters were then 
submerged in 1 mL of (1 M) formic acid and vortexed for 30 sec to break the cell walls. 
After removing the filters, the samples were centrifuged for 10 min at 14,000 RPM. Four 
hundred microliters of supernatant was lyophilized using a speed vacuum for 4 h. Finally, 
the pellets were resuspended in 80 µl of (0.1 M) HCl (BYRNE and HOFFMAN 1993). 
Assay was performed using cAMP Direct Kit (Assay Designs). 
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2.2.16. Protein extraction for cAMP  
Cells were pelleted and washed with cold water. The cell pellet then was resuspended in 
500 µl of 0.2 N NaOH. Half of the suspension was transferred into a microcentrifuge tube 
with 0.4 g glass beads. The tubes were then vortexed for 3 min to break the cells. The 
samples were boiled for 3 min followed by centrifugation for at 14,000 RPM for 2 min to 
remove cell debris. Protein quantification was preformed using the BCA kit.  
 
2.2.17. Plasmid rescue from yeast (Smash and Grab)  
Smash and Grab protocol was used to rescue plasmid from yeast (HOFFMAN and 
WINSTON 1987). Cells were grown in selective liquid medium for overnight. Then 
cultures were pelleted, resuspended, and vortexed with glass beads, 0.2 mL phenol-
chloroform, and 0.2 mL of Smash and Grab buffer made as described by Hoffman and 
Winston (HOFFMAN and WINSTON 1987). The cells were then centrifuged for 5 min and 
the supernatant containing the isolated plasmid was transferred to a new tube.  
 
2.2.18. Escherichia coli transformation 
Escherichia coli transformations were done using Ten-Blue or XL1-Blue electroporation-
competent cells (Stratagene). 
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2.2.19. Yeast transformation  
Cells were grown in YEL overnight to early log phase 5x10
6
. Cells were pelleted and 
washed twice with cold water and (LiAc/TE) buffer. Pellets were resuspended in 100 µl 
LiAc/TE and mixed with 1 µl boiled salmon testes DNA and 5-10 µl of the sample DNA. 
The samples were kept for 10 min in room temperature before adding 260 µl of (40% 
PEG, 100 mM LiOAc, 10 mM Tris-HCl pH 7.5) buffer. Samples were then incubated at 
30°C for 1 h. The samples then were heat shocked for 5 min at 42°C after adding 43 µl of 
DMSO to the samples. Finally, cells in different dilutions were plated on selective 
medium (BÄHLER et al. 1998). Transformation was also, performed by growing yeast on 
YEA medium for overnight at 30°C. Cells were then collected directly on the plate and 
resuspended in PLATE (40% PEG; 10 mM Tris HCl, 100 mM LiOAc; 1mM EDTA). 
Next, 100 µl of the mixture was used for each transformation with 1 µl boiled salmon 
testes DNA and 5-10 µl of the sample DNA. The samples were incubated at 30°C for 24 
h before they were plated on selective medium. 
 
2.2.20. Microscopy 
The images of cells were captured using a Zeiss microscope with an Orca-ER CCD 
camera. The microscope –camera are connected to a computer equipped with Openlab 
software. Strains were grown in appropriate liquid media to 2-4x106 cells/mL, then cells 
were fixed with paraformaldehyde as previously described (HAGAN and HYAMS 1988) 
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with some modification. Yeast cell walls were digested with 0.5 mg/mL 100T 
Zymolyase. The Hsp90 V5-tagged protein was detected by using α-V5 primary mouse 
antibody (Invitrogen) diluted 1:100 in PEMBAL. The endogenous Hsp90 protein was 
detected by using α-Hsp90 (K41220) primary mouse antibody diluted 1:100 in 
PEMBAL. Both were visualized using secondary antibody Alexa Fluor 488-labeled goat 
α-mouse (Molecular Probes) diluted 1:50 in PEMBAL overnight in the dark. The 
Fluorescence Alexa Fluor 488-labeled antibodies signals were visualized under 
fluorescein isothiocyanate (FITC) filter. Localization of Hsp90 was captured using a 
Nikon confocal microscope system with a Nikon Eclipse inverted microscope and EZC1 
Software system.  Hoechst 33342 was also used to stain the nuclei. Septum was stained 
using calcofluor. Both were visualized under 4', 6-diamidino-2-phenylindole (DAPI) 
filter. 
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CHAPTER THREE 
CLONING AND CHARACTERIZING git10+ 
This chapter is published as a research article in Genetics, Vol. 178, 1927-1936, 
April 2008 
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CLONING AND CHARACTERIZING git10+ 
 
3.1. Genetic mapping and cloning of the S. pombe git10+ gene 
 Git- mutant strains display 5FOA-sensitive (5FOAS) growth due to their inability to 
glucose repress the fbp1-ura4+ reporter (HOFFMAN and WINSTON 1990). To date, nine git 
genes have been shown to play a significant role in fbp1+ repression, with only git10+ 
remaining to be cloned.  Due to the large number of multicopy suppressors encountered 
when screening plasmid libraries during attempts to clone genes in this pathway (DAL 
SANTO et al. 1996; HOFFMAN and WINSTON 1991; JIN et al. 1995; WANG et al. 2005b),  a 
genetic mapping approach to identify the git10+ gene was performed. 
 
Chromosomal mapping of git10-201 by benomyl-induced haploidization of an h-/mat2-
102 diploid strain (ALFA et al. 1993) was carried out with strains FWP17 and CHP573 
(Table 1). This technique allows the formation of haploids from a diploid strain in the 
absence of meiotic recombination, such that the alleles on each of the three parental 
chromosomes form individual linkage groups. All 5FOA-sensitive haploids produced this 
way possessed chromosome 2 from CHP573, containing the fbp1-ura4+ reporter, as well 
as chromosome 1 from CHP573, presumably possessing git10-201 (data not shown). The 
git10-201 allele was further mapped by tetrad dissection, in a cross of strain FWP87 with 
strain CHP894.  
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Figure 9.  Git10 cloning process 
(A) The git10+ gene maps between lys1 and cdc1+. The genetic mapping data suggested that git10+ is 
present on cosmid SPAC926. (B) PCR amplification of SPAC926 was divided into nine fragments and then 
these fragments were TOPO-cloned into plasmids that were used to transform S. pombe strain CHP567. 
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Figure 9. 
 
A. 
 
 
 
B. 
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The git10+ gene maps between lys1+ (23.2 cM with a PD:TT:NPD ratio of 45:39:0) and 
cdc1+ (30.4 cM with a PD:TT:NPD ratio of 38:45:1). The lys1+ and cdc1+ genes are 54.8 
cM from each other with a PD:TT:NPD ratio of 22:56:6.  
 
The genetic mapping data suggested that git10+ is present on cosmid SPAC926 (one of an 
ordered set of cosmids used in the S. pombe genome sequencing project (Figure 9) 
(WOOD et al. 2002). Insert DNA from SPAC926 was divided into nine fragments by PCR 
amplification and TOPO-cloning into a plasmid suitable for transformation of S. pombe.  
Plasmids from this set of clones were used to transform S. pombe strain CHP567 (git10-
201) to Leu+ and transformants were tested for restoration of 5FOA-resistance to indicate 
complementation of the git10- defect. Plasmids pMAR1 and pMAR2, which carry 
fragment number 7, base pairs 2308 to 9026 in either orientation with respect to the 
vector, were the only clones to confer 5FOA-resistance (Figure 10A). These 
transformants also glucose-repress fbp1-lacZ expression as judged by β-galactosidase 
assays (Figure 10B). Plasmids pMAR1 and pMAR2 contain two genes, one of which is 
hsp90+/swo1+. Digestion with NruI followed by ligation removed a 1.4 kb fragment 
internal to the hsp90+ open reading frame and produced plasmids pMAR1A and 
pMAR2B, which lost the ability to suppress the git10-201 mutation (Figure 10). Thus, 
hsp90+ appears to be responsible for suppression of the git10-201 mutant allele.  
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Figure 10. Complementation of git10-201 mutation by plasmid-expressed git10+.  
(A) CHP567 (git10-201) cells were transformed to Leu+ with pNMT41 (empty vector), pMAR1 (git10+), 
pMAR1A (git10∆236-1607), pMAR2 (git10+ cloned in the opposite orientation to that of pMAR1), 
pMAR2B (git10∆236-1607 cloned in the opposite orientation to that of pMAR1A). The git10∆236-1607 
contains a partial dropout of the git10 ORF. The two independent transformants of each plasmid indicated 
in the Figure were spotted on EMM–leu and then replica plated after 2 days to EMM–leu and 5FOA plates. 
Plates were photographed after three days incubation at 30ºC. (B) ß-galactosidase activity was determined 
as described in MATERIALS AND METHODS. The values represent the average ± standard deviation of 
at least two independent transformants.  
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Figure 10. 
 
 
 
A.      B. 
 
 
 
 
 
 
 
 
 
 
 58 
Figure 11. Complementation of git10-201 mutation by plasmid expressed git10-V5 
Plasmid pMAR3 carries only the hsp90 ORF, while plasmids pMAR1 and pMAR2 carry larger segments 
of the chromosomal DNA that include the hsp90+ gene. Plasmid pMAR3 complements the git10-201 
mutation whereas pNMT41 (empty vector) does not. Transformants were spotted on EMM–leu and then 
replica plated after 2 days to EMM–leu and 5FOA plates. Plates were photographed after three days 
incubation at 30ºC. 
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Figure 11.  
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To confirm that hsp90+ is git10+, plasmid pMAR3 was constructed to express an epitope-
tagged form of Hsp90 (see Materials and Methods). CHP567 (git10-201) transformants 
carrying pMAR3 are 5FOA-resistant (Figure 11) proving that hsp90+ is able to suppress 
the git10-201 mutation.  In contrast, transformation by pMAR3 fails to suppress the PKA 
pathway mutations git1-, git2- (cyr1-), git7- or pka1- (Figure 12). 
 
3.2. Hsp90 is required for nutrient regulation of sexual development  
Wild type S. pombe requires either a glucose or a nitrogen starvation signal to initiate 
mating and meiotic entry (STETTLER et al. 1996). Consequently, mutations in genes 
required for glucose/cAMP signaling allow cells to mate and sporulate even in a nutrient-
rich medium (ISSHIKI et al. 1992; JIN et al. 1995; KAO et al. 2006; LANDRY and 
HOFFMAN 2001b; LANDRY et al. 2000; MAEDA et al. 1990; SCHADICK et al. 2002; 
WELTON and HOFFMAN 2000). Consistent with a role in this pathway, the git10-201 allele 
of hsp90+ allows homothallic (h90) cells to mate in a glucose-rich medium, as evidenced 
by presence of meiotic asci (Figure 13). This starvation-independent mating is similar to 
that conferred by deletion of the adenylate cyclase gene (git2+) or the Gß subunit gene 
(git5+; Figure 13).  Addition of 5 mM cAMP to the medium suppresses conjugation in all 
three mutant strains (Figure 13). This starvation-independent, cAMP-suppressible defect 
in the regulation of sexual development is another indication that Hsp90 plays a role in 
the S. pombe glucose/cAMP signaling pathway. 
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Figure 12. Test if git10/hsp90 can act as a high-copy suppressor of mutations in 
other genes in the glucose-sensing cAMP pathway 
Plasmid pMAR3 was expressed into strains carrying mutations in git1+, git2+, git7+, git10+, and pka1+. All 
of these transformants remain 5-FOA-sensitive. On the contrary, plasmid pMAR3 was able to suppress the 
git10-201 mutation. 
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Figure 12. 
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Figure 13. Homothallic git10-201 cells conjugate and sporulate in nutrient-rich medium 
Homothallic git10-201 cells conjugate and sporulate in nutrient-rich medium, similar to other cAMP 
pathway mutants. Homothallic (h90) strains CHP362 (git10+), CHP558 (git2Δ), CHP486 (git5Δ), and 
MAP1 (git10-201) were grown to exponential phase in PM liquid medium (8% glucose) at 37°C (to inhibit 
conjugation), diluted to 106 cells/ml in PM liquid medium in the presence or absence of 5 mM cAMP, and 
incubated overnight at 30°C without shaking.  Starvation-independent conjugation and sporulation, which 
is suppressible by addition of cAMP, is observed in all three mutant strains.   
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Figure 13. 
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Furthermore, a mutation in any gene required for glucose-cAMP signaling will result in a 
defect in the glucose repression of fbp1-lacZ expression and 5FOA sensitive phenotype 
(ISSHIKI et al. 1992; LANDRY and HOFFMAN 2001; LANDRY et al. 2000; MAEDA et al. 
1990; WELTON and HOFFMAN 2000). Therefore, a mutation in git10/hsp90 ORF should 
confer a Git- mutant phenotype, an elevated fbp1-lacZ  expression in cells grown under 
glucose-rich conditions (Figure 10B) and 5FOA sensitive growth due to constitutive 
expression of the fbp1-ura4+ reporter (Figure 10A). These results demonstrate that 
git10/hsp90 is required for the cAMP-dependent regulation of conjugation, as well as 
fbp1 transcriptional regulation. 
 
3.3. Genetic, environmental, and chemical insults to Hsp90 activity derepress fbp1-
lacZ expression 
 To investigate the role of Hsp90 in the regulation of fbp1+ transcription, ß-galactosidase 
activity expressed from the fbp1-lacZ reporter was measured in wild type, git10-, and 
swo1- mutant strains grown at various temperatures (Table 2).  Both the swo1-21 and 
swo1-26 alleles confer a temperature-dependent defect in fbp1-lacZ repression, in 
addition to a temperature-sensitive growth defect.  
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Table 2. Glucose repression of fbp1-lacZ expression as a function of growth 
temperature 
 
         ß-galactosidase activity    
Strain       hsp90 allele         25º      27º        30º       32º        37º    
FWP87 wild type   15±5   11± 0   10 ±6   12 ± 4              392±6 
CHP567 git10-201 154±20    252 ±26 626±30 661±157 1336±131 
CHP981 swo1-26   54±3  144 ±5 517±55 Inviable Inviable 
CHP989 swo1-21 157±12   377±8  605±105 Inviable Inviable 
  
ß-galactosidase activity was measured in cells growing in YEL medium under glucose-
repressing conditions (8% glucose) for 18 hours at the indicated temperature. The values 
given represent specific activity average ± standard deviation from two or three 
independent cultures. 
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The git10-201 allele also confers a temperature-dependent defect in fbp1-lacZ repression, 
however these cells remain viable when cultured at 37ºC. Surprisingly, wild type cells 
display a partial defect in fbp1-lacZ repression when cultured at 37ºC, suggesting that 
temperature stress of wild type cells leads to a reduction in PKA activity, and not simply 
the activation of the Spc1/Sty1 MAPK required for fbp1+ transcription. 
The effect of temperature stress on fbp1-lacZ repression was further examined in a time-
course experiment in which wild type cells were cultured at 30ºC or 40ºC, a temperature 
that does not support growth of S. pombe, but at which cells remain viable for several 
days (C.A. Hoffman and C.S. Hoffman, unpublished results). Increased ß-galactosidase 
activity in response to temperature stress can be detected within one hour (data not 
shown), although it remains modest even after six hours of incubation (Figure 14A). By 
24 hours, however, the ß-galactosidase activity rises to 547 ± 80 units, demonstrating that 
prolonged exposure to heat stress is required for significant fbp1+ derepression. As the 
glucose levels in the media remain above 7.5% in all cultures, the increased fbp1-lacZ 
expression is due to heat stress and not glucose starvation (Figure 14B). 
To independently test whether Hsp90 is required for fbp1+ regulation, I examined the 
effect of chemical inhibition of Hsp90 on fbp1-lacZ expression by exposing cells to the 
Hsp90 inhibitor geldanamycin (WHITESELL et al. 1994).   
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Figure 14.  Prolonged heat stress derepresses fbp1-lacZ transcription.  
 (A) Wild type strain FWP77 was pregrown to exponential phase at 30º and then subcultured at 30º or 40º in 
YEL medium under glucose-repressing conditions. ß-galactosidase activity was measured at the times 
indicated. The values given represent specific activity average ± standard deviation from two or three 
independent cultures. (B) Glucose levels of the same samples were measured. 
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Figure 14. 
 
A. 
 
 
B.  
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ß-galactosidase activity was measured from wild type strain FWP77 cells grown at 30ºC 
for 18 hours in the presence or absence of geldanamycin (2 µg/ml, 5 µg/ml, 10 µg/ml).  
There was a clear dose-dependent derepression of fbp1-lacZ expression, although the 
levels of expression did not reach those detected in cells subjected to prolonged heat 
stress (Figure 15). 
3.4. Phenotypic differences between swo1- and git10- alleles of hsp90+ 
In the course of assaying ß-galactosidase activity from swo1- and git10- strains, I 
confirmed previous observations that indicated that the swo1- alleles confer temperature 
sensitive growth (ALIGUE et al. 1994), while the git10-201 allele does not. 
 
For a more rigorous comparison, I carried out spot tests on hsp90+, swo1-26, swo1-21, 
and git10-201 strains to examine growth on rich medium at 25º, 28º, 30º, and 37ºC. Both 
swo1- mutants display a severe temperature-sensitive growth defect, even at 30ºC, while 
the git10-201 mutants only displays a slow growth phenotype at 37ºC rather than a loss of 
cell viability (Figure 16). 
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Figure 15. Chemical inhibition of Hsp90 derepress fbp1-lacZ transcription 
ß-galactosidase activity was measured in cells growing in 8% glucose YEL medium for 18 hours in the 
presence of the Hsp90 inhibitor geldanamycin at the indicated concentrations.  The values given represent 
specific activity average ± standard deviation from two or three independent samples. 
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Figure 15. 
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Figure 16. Temperature-dependent growth of hsp90+, swo1-26, swo1-21, and git10-201 strains 
Spot tests were carried out on YEA rich medium at 25º, 28º, 30º, and 37ºC. Strains FWP72 (wild type), 
CHP567 (git10-201), CHP989 (swo1-21), CHP979 (swo1-26), were cultured to 1 x 107 cells/ml in YEL 
liquid medium. Cells were washed with YEL medium and adjusted to 2 x 107 cells/ml and subjected to five 
10-fold serial dilutions. Five microliters of each culture was spotted to a YEA plate and grown for 3 days at 
indicated temperature before photographing. 
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Figure 16. 
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Microscopic examination of hsp90+, swo1- and git10-201 strains growing at 28º, 30º, and 
37ºC was carried out to examine the nature of the temperature-dependent growth defect. 
After 24 hours growth on EMM defined medium, the swo1-21 strain displayed abnormal 
cells that were lysed or binucleate or with misplaced nuclei in cultures grown at 30°C and 
37°C (Figure 17). The swo1-26 strain appeared normal at 30ºC, while most cells had 
improperly placed nuclei at 37º.  These results contrast somewhat with those from the 
spot test of a swo1-26 strain at 30ºC (Figure 16), and appears to be a medium-specific 
effect with these cells displaying a more severe growth defect on YEA rich medium than 
on EMM defined medium as seen in Figure 18.   
 
No growth defects were observed in wild type or git10-201 cells at any temperature 
(Figure 16,17), distinguishing the cAMP pathway defect caused by the git10-201 
mutation from the cell growth defects caused by the swo1-21 and swo1-26 mutations. 
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Figure 17. Temperature-dependent morphology of hsp90+, swo1-26, swo1-21, and git10-201 strains.   
Strains were precultured at 28ºC and then transferred to EMM defined medium and grown for 24 hours at 
28, 30, and 37°C.  Cells were heat-fixes and stained with Hoechst 33342 and Calcofluor.  Images were 
visualized and captured using a Zeiss Axioplan2 microscope with an Orca-ER CCD camera and Openlab 
software. The swo1-21 strain displayed lysed or binucleate cells at 30ºC (Red Arrows). The swo1-26 30ºC 
cells had improperly placed nuclei at 37ºC (Red Arrowheads). The git10-201 cells appeared normal.  
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Figure 17.  
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Figure 18. Cell morphology of hsp90+, swo1-26, swo1-21, and git10-201 strains at 30°C on YEA  
The same strains as shown in Figure 16 were precultured at 28ºC and then transferred to YEA instead of 
defined medium (EMM) and grown for 24 hours at 28°C, 30°C. Cells were heat-fixed and stained with 
Hoechst 33342 and Calcofluor. Hsp90 mutant strains appeared normal at 28°C (data not shown) but show 
defects at 30°C. These cells display more severe growth defect (Arrowheads) on YEA rich medium than on 
EMM defined medium. 
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Figure 18. 
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3.5. Sequence analysis of swo1- and git10- alleles 
 The sequence of the entire hsp90+ open reading frame was determined from strains 
carrying the swo1-21, swo1-25, swo1-26, and git10-201 alleles.  The swo1-25 and swo1-
26 alleles carry the same mutation, changing residue 84 from glycine to cysteine, while 
the mutation in swo1-21 changes residue 654 from leucine to arginine. The git10-201 
allele changes residue 338 from leucine to proline (Figure 19).  Thus, the swo1-25 and 
swo1-26 alleles affect the N-terminal ATP-binding domain, the swo1-21 allele affects the 
C-terminal dimerization domain, and the git10-201 allele affects the central, client 
protein-binding domain.  
 
The locations of these mutations are consistent with the observations that the swo1- 
mutant alleles appear to be general reduction-of-function alleles, while the git10-201 
mutation appears to confer only a modest growth defect, but a significant defect in 
glucose/cAMP regulation of fbp1+ transcription. A similar separation-of-function allele of 
an Hsp90 gene daf-21 has been observed in the cGMP signaling pathway of the nematode 
Caenorhabditis elegans (BIRNBY et al. 2000). The daf-21 mutation as seen in Figure 19 
and Figure 20 is a missense mutation that alters a residue in the Hsp90 central domain not 
far from the residue altered by the S. pombe git10-201 mutation. 
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Figure 19. Alignment of Hsp90 proteins from S. pombe, S. cerevisiae, and C. elegans  
The S. pombe Hsp90 protein (accession number CAB54152) was aligned using ClustalW (THOMPSON et al. 
1994) with the S. cerevisiae Hsc82 protein (accession number CAA89919), C.elegans DAF-21 (accession 
number NP_506626), human Hsp90α (accession number NP_005339), and displayed using BOXSHADE 
3.21. Identical residues are shaded in black, while conserved residues are shaded in gray. Amino acid 
changes associated with the swo1-21, swo1-26, and git10-201 mutant alleles are also indicated, as well as 
that of the C. elegans daf-21 mutation. 
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Figure 19. 
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Figure 20. Crystal structure of the central domain of S. cerevisiae Hsp82  
Hsp82 (accession number AAA02813) showing the location of the residues altered by the S. pombe git10-
201 mutation and the C. elegans daf-21 mutation. The two altered residues are on the same surface of the 
Hsp90 central domain. The graphic image was created using Pymol (DeLano Scientific). 
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Figure 20.  
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The similarity between these two mutations and their associated phenotypes suggest that 
Hsp90 plays a similar role in both S. pombe and C. elegans cyclic nucleotide signaling 
pathways to regulate metabolic pathways in response to temperature and nutritional 
conditions (See summary and future directions).  
 
3.6. Hsp90 localization in S.pombe  
I examined Hsp90 localization using indirect immunofluorescence microscopy on cells 
carrying plasmid pMAR3 (nmt41-Hsp90-V5) and cells carrying an empty vector. The 
signal was detected using α Hsp90 antibody (K41220) against the Hsp90-V5 and the 
endogenous Hsp90 (Figure 21). Cytoplasmic punctate was observed throughout the 
cytoplasm of the cell. This is not surprising as Hsp90 is likely to be one of the most 
abundant proteins in S. pombe. 
 
The localization of endogenous Hsp90 appears the same as Hsp90-V5 although the 
endogenous signal was less intense than the expressed form of Hsp90. These results 
suggest that the immunofluorescent signal using that was observed is real and the Hsp90 
antibody (K41220) is recognizing Hsp90 specifically since the signal was induced when 
Hsp90 was overexpressed. Previous studies in our lab showed similar cytoplasmic 
punctate pattern of other components of the glucose/cAMP pathway including Git1 (KAO 
et al. 2006), Git2 (Wang, unpublished data), and Git7 (SCHADICK et al. 2002) but not 
Git3 (Chandler, unpublished data). 
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Figure 21. Subcellular localization of Git10/Hsp90  
 DIC and fluorescent images of cells expressing tagged Hsp90 to detect the overexpressed Hsp90-V5 as 
indicated. Endogenous Hsp90 was detected using Hsp90 antibodies (K41220). The overexpressed Hsp9-
V50 was detected using αV5 antibodies. Empty vector (EV) and αV5 antibodies was used as a control. 
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Figure 21.  
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Hsp90 Works Together with Git7 in Schizosaccharomyces pombe 
 
4.1. Git7 Interacts With Hsp90 and Requires Functional Hsp90 
 
4.1.1. Sensitivity of git7 mutants to a specific inhibitor of Hsp90 
In the previous chapter, I showed that git10/hsp90 is identical to swo1+, which encodes 
the S. pombe Hsp90 protein. This discovery shed light on the earlier identification of the 
Git7 protein as a member of the Sgt1 family in S. cerevisiae (SCHADICK et al. 2002). Git7 
and Hsp90 are both found to be important in proper cAMP signaling in S. pombe. 
Mutations in any of these genes causes elevated levels of   fbp1gene transcription in cells 
grown in the presence of glucose (HOFFMAN and WINSTON 1990; HOFFMAN and 
WINSTON 1991). To investigate whether the function of Git7 involves Hsp90, I used a 
pharmacological approach to understand the role of Hsp90 and Git7. I monitored the 
growth of wild-type, Git7 mutants, and Hsp90 mutants on YEA plates in the presence of 
a low (2 µg/ml) to high dose (10 µg/ml) of geldanamycin (GA), or Dimethyl sulfoxide 
(DMSO) and observed their ability to form colonies at the permissive temperature. The 
same temperature sensitive Git7 mutants, git7-27, git7-235, as well Hsp90 temperature 
sensitive mutants swo1-21, swo1-26 (Figure 22, 23) displayed drug sensitivity even under 
low doses of geldanamycin.  
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Figure 22. Temperature-dependent growth of wt, git7-235, git7-27, git7-93, swo1-26, swo1-21, and 
git10-201 strains 
The git7-235 and swo1- mutants display a severe temperature sensitive growth phenotype. The git7-93 
mutant grows well at 37ºC, while the git10-201 mutant shows only a partial reduction in growth at 37ºC. 
Spot tests were carried out on YEA rich medium at the indicated temperature. Strains FWP72 (wild type), 
CHP465 (git7-235), CHP27 (git7-27), CHP800 (git7-93), CHP567 (git10-201), CHP989 (swo1-21), and 
CHP979 (swo1-26) were cultured to 1 x 107 cells/ml in YEL liquid medium. Cells were washed with YEL 
medium and adjusted to 2 x 107 cells/ml and subjected to five 10-fold serial dilutions. Five microliters of 
each culture was spotted to a YEA plate and grown for 3 days at the indicated temperature before 
photographing. 
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Figure 22.  
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Figure 23. The git7 mutants and hsp90 mutants display severe drug sensitivity 
git7 mutants and hsp90 mutants show geldanamycin sensitivity whereas, git7-93 mutant grows well even in 
the presence of high concentration of geldanamycin (GA). Spot tests were carried out on YEA rich medium 
containing (2 µg/ml), (5 µg/ml), and (10 µg/ml) of geldanamycin (GA), or Dimethyl sulfoxide (DMSO) at 
the permissive temperature (28ºC). Strains FWP72 (wild type), CHP465 (git7-235), CHP27 (git7-27), 
CHP800 (git7-93), CHP567 (git10-201), CHP989 (swo1-21), CHP979 (swo1-26) were cultured to 1 x 107 
cells/ml in YEL liquid medium. Cells were washed with YEL medium and adjusted to 2 x 107 cells/ml and 
subjected to five 10-fold serial dilutions (left to right). Five microliters of each culture was spotted to a 
YEA plate and grown for 3 days at the indicated temperature before photographing. 
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Figure 23.  
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These results are consistent with the previous finding in Saccharomyces cerevisiae where 
sgt1 temperature-sensitive mutants showed sensitivity to geldanamycin (BANSAL et al. 
2004; DUBACQ et al. 2002). Surprisingly, a strain carrying the git7-93 allele, which 
contains duplication in the C-terminal coding region showed neither temperature 
sensitivity nor a geldanamycin supersensitive effect (Figure 22, 23). 
 
4.1.2. Association of Git7 with Hsp90 in Schizosaccharomyces pombe 
The Git7 protein is a member of the Saccharomyces cerevisiae Sgt1 protein family. 
Recent studies show that Sgt1 interacts with Hsp90 in S. cerevisiae (KITAGAWA et al. 
1999) in Arabidopsis (TAKAHASHI et al. 2003) and in humans (LEE et al. 2004). The 
structures of Git7/Sgt1 proteins and Hsp90 are highly conserved and their functions are 
essential for viability in yeast and plants. It was also suggested that Sgt1 might act as an 
Hsp90 co-chaperone in S. cerevisiae (DUBACQ et al. 2002; SCHADICK et al. 2002)  
To test if Hsp90 and Git7 interact in S. pombe, I carried out an immunoprecipitation 
experiment in wt, git7-235, git7-27, git7-93, and in git10-201 strains using α-Sgt1 
antibodies that have been shown to cross-react with Git7 (CHARLTON, 2005). The 
specificity of the immunoprecipitation was confirmed by western blot analysis. Previous 
efforts to precipitate Hsp90 and Git7 have been unsuccessful (CHARLTON, 2005). 
Therefore, the immunoprecipitation protocol was repeated with some modification. One 
important alteration was performing protein extraction in liquid nitrogen instead of using 
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the Bead Beater (See Material and Methods).  
Although, little to no interaction between Hsp90 and Git7 was observed in the wild type 
strain, I was able to demonstrate the presence of Hsp90 in the Git7 immunoprecipitates in 
git7 mutants and git10-201. The interaction was modest in git7-93, and greater in git7-27 
strain. A significant interaction was observed between Git7 and Hsp90  in git7-235 strain  
which has a mutation in the N-terminus and in git10-201/hsp90-201 strain  which has a 
mutation in the middle domain of Hsp90 (Figure 24; See summary and future directions). 
 
4.1.3. Git7 requires a functional Hsp90 to maintain cell wall integrity, normal 
septation and proper cAMP signaling  
Previous analysis showed that Git7 has additional essential functions that are unrelated to 
cAMP signaling. The git7 temperature sensitive mutants developed cytokinetic defects 
when incubated at the restrictive temperature (SCHADICK et al. 2002). This led to test if 
Git7 needs Hsp90 to be able to carry out these functions properly. Therefore, I tested 
whether the previous cytokinetic defect of the git7 mutants was due specifically to the 
need of functional Hsp90. 
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Figure 24. Git7 and Hsp90 interact in Schizosaccharomyces pombe 
Immunoblot of protein extracts probed with Hsp90 antibodies (K41220) from α-Sgt1 immunoprecipitation. 
Cells were grown under repressing conditions (3% glucose). Protein extracts were prepared from strains 
MAP12 (wt), CHP465 (git7-235), CHP27 (git7-27), MAP10 (git7-93) and CHP567 (git10-201) by grinding 
cells in liquid nitrogen as described in the Material and Methods. Approximately 30 µl of protein extracts 
were loaded into a 4%-15 SDS-PAGE gradient gel. Crude extracts, along with fractions that bound or 
failed to bind an α-Sgt1 antibodies, were probed with Hsp90 antibodies and visualized at approximately 90 
kDa. Note that Git7 protein detection in the bound lane was hindered due to the fact that Git7 is 
approximately 43 kDa in size and runs at the same mobility of the IgG heavy chain. 
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Figure 24.  
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This test was possible by using geldanamycin (GA), a specific Hsp90 inhibitor. Wild type 
cells, Git7 mutants, and Hsp90 mutants were grown under the permissive temperature 
(28ºC) in the presence of (GA) (Figure 25A). For comparison, the same strains were also 
grown at restrictive temperatures (30ºC, 37ºC) (Figure 25B). The cells were fixed by heat 
and stained with Hoechst 33342 and Calcofluor to visualize the nuclei and septa, 
respectively. Interestingly, the same cytokinesis defects that were detected in Git7 and 
Hsp90 temperature sensitive mutants at restrictive temperatures were seen in these cells 
treated with the geldanamycin at permissive temperatures. The wild-type strain showed 
mononucleate cells, while the git7-235, git7-27, swo1-21 and swo1-26 strains contained 
mainly multinucleate cells and a multiseptum phenotype in the presence of the drug, 
which is consistent with the temperature dependent phenotype.  
 
Consistent with git7-93 being a separate-of-function allele, git7-93 exhibited no defect in 
the presence of geldanamcyin. In contrast, git7-235 showed a severe defect of elongated 
multinucleated cells in the presence of geldanamycin. This phenotype was also observed 
at elevated temperatures (Figure 25A,B). The git10-201 strain showed moderate 
temperature sensitivity and only moderate sensitivity to geldanamycin (Figure 22, 23). 
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Figure 25. Cells display morphological defects in Hsp90 and Git7 mutants under elevated 
geldanamycin or temperature, but not in git7-93 and wt strains 
(A) Geldanamycin-dependent morphology of wt, git7-27, git7-235, git7-93, swo1-26, swo1-21, and git10-
201 strains. Strains were grown in the presence of geldanamycin at the permissive 28°C for 18 hours. (B) 
Temperature-dependent morphology of wt, git7-27, git7-235, git7-93, swo1-26, swo1-21, and git10-201 
strains. Strains were precultured at 28º and then transferred and grown for 18 hours at 28°C, 30°C and 
37°C.  Cells were heat-fixed and stained with Hoechst 33342 and Calcofluor. Red arrows indicate 
multinucleate cells. Red arrowheads indicate multi septum cells.  
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Figure 25. (A) 
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(B) 
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The git7 ts alleles (git7-27 and git7-235) and swo-1 alleles of hsp90 confer a cell 
septation and a temperature/geldanamycin sensitive phenotype not observed in git7-93 
strain and seen mildly in git10-201 (Figure 25A,B) suggesting that both Git7 and Hsp90 
have a separate and independent role from cAMP. Cells lacking adenylate cyclase did not 
show abnormal morphology even under high concentration of geldanamycin consistent 
with the idea that cAMP defect is not the cause of the septation defect (Figure 26). 
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Figure 26. Cells display no morphological defects in git2 deletion strain under elevated geldanamycin 
concentration 
Cells display no morphological defects in git2 deletion (FWP190) or wild type (FWP72) strains under 
elevated geldanamycin concentration whereas (CHP567) git10-201 strain displayed multinucleate cells at 
high concentration of geldanamycin. Strains were precultured in 8% glucose YEL medium at 30ºC and then 
transferred and grown for 26 hours at 30°C in the presence of geldanamycin. Cells were heat-fixed and 
stained with Hoechst 33342 and Calcofluor.  
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Figure 26. 
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4.2. Hsp90 and Git7 Act in the Assembly of the cAMP Signaling Complex 
 
4.2.1.  Hsp90 and Git7 are not regulated by glucose unlike other proteins of cAMP 
Pathway 
Glucose concentration had no effect on Hsp90 and Git7 protein abundance, unlike Git1 
and Git2 (Protein proven to be part of the cAMP core complex). MAP5 strain expressing 
GFP-tagged Hsp90, V5-tagged Git1 and Myc-tagged Git2 were cultured in YEL 0.1% 
glucose (derepressing) and YEL 8% glucose (repressing conditions). 
 
Protein extraction and immunoblot analysis showed no significant change of Hsp90 
abundance in either condition, whereas Git1 and Git2 were significantly affected (Figure 
27). Similar to Hsp90, Git7 levels do not appear to be regulated by glucose (CHARLTON,  
2005). Despite that a mutation in either the git7 or hsp90 genes can result in high β-
galactosidase activity for an fbp1-lacZ reporter, Hsp90 and Git7 protein levels were not 
regulated by the glucose conditions. In contrast, Git1 and Git2 protein levels were 
regulated by glucose conditions (Figure 27). Grandy, 2004 from Hoffman lab had also 
demonstrated that glucose addition to starved cells causes approximately a twelve-fold 
decrease in the transcription of git1 and a thirteen-fold decrease of git2 after thirty 
minutes of glucose addition (GRANDY, 2004). 
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Figure 27. Hsp90 protein levels are not regulated by glucose; Git1 and Git2 are regulated by glucose 
conditions  
Immunoblot analysis of protein extracts obtained from a MAP5 a wild type strain harboring GFP-tagged 
Hsp90, V5-tagged Git1, and Myc-tagged Git2. Cells were grown under glucose-repressing/glucose rich (R) 
or derepressing/glucose starved (D) conditions. Actin was used as a loading control.  
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Figure 27. 
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Therefore, glucose might directly affect the core component of the cAMP complex (Git1 
and Git2), but not proteins required for complex assembly (Hsp90 and Git7; See 
summary and future directions). 
 
4.2.2. Significant delay between inhibition of Hsp90 and defect in glucose signaling  
I have already proven that Hsp90 and Git7 work together in S. pombe. In order to 
understand the role of these proteins in cAMP pathway, I wanted to test the involvement 
of Hsp90 in the stabilization of key players in cAMP pathway and to investigate Hsp90’s 
possible involvement in the assembly of cAMP complex. Hsp90 is a chaperone that is 
involved in stabilizing multiple signaling complexes in the cell. The form of Hsp90 
required for chaperone activity is the ATP-bound form that allows regulation of the 
stability of proteins, and permits their activation in signaling cascades. In contrast, when 
Hsp90 is in the Hsp90-ADP form, its clients will be targeted to the proteasome for 
degradation. Geldanamycin (GA) is a drug that binds the N-terminal ATP-binding site of 
Hsp90 and will lock Hsp90 into the inactive form (ADP form). This will result in 
inhibiting Hsp90 normal function and subjecting its targets to degradation (Figure 6). 
Therefore, this drug has been widely used to study the role of Hsp90 in modulating the 
function of signaling proteins, and to aid in Hsp90 client discovery. 
 
In Chapter 3 (Figure 15) I demonstrated that GA treatment affected fbp1-lacZ expression. 
When I examined the effect of geldanamycin (GA) (2, 5, 10 µg/ml) on fbp1-lacZ 
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expression after 18 hours there was a clear dose-dependent derepression of fbp1-lacZ 
expression, although the levels of expression did not reach the levels of that detected in 
cAMP/glucose mutants. To further test this observation at the protein level, I tested the 
effect of disrupting Hsp90 using GA on some key players in the glucose/cAMP pathway. 
After exposing a strain (MAP5) that carries tagged forms of Git1, Git2, and Hsp90 to GA 
for 18 h, cells were harvested and total protein was extracted by a TCA precipitation 
method (see Materials and Methods). By conducting immunoblot analyses against the 
endogenous Git1-V5, Git2-Myc, Gpa2, Hsp90 –GFP and Actin I determined whether the 
Git1, Git2, or Hsp90 protein levels were affected by GA treatment (Figure 28). In a dose-
dependent manner, GA significantly reduced Git1, Git2 and Gpa2 protein levels. In 
contrast, Hsp90 and Actin levels were not affected (Figure 28). These results demonstrate 
that functional Hsp90 is important for cAMP signaling since components of this signaling 
pathway were notably affected.  
 
Therefore I investigated how long it would take GA to have an effect on Git1, and Git2 
after drug treatment. MAP5 strain was grown in 3% glucose YEL medium for overnight 
to log phase. A time course experiment was performed using high does of GA (10 
µg/ml).  
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Figure 28. Hsp90 inhibition affects the stability of cAMP components after 18 hours of drug addition  
Cells were treated for 18 h with an increased amount of GA (2 µg/ml, 5 µg/ml, 10 µg/ml). Equivalent 
amounts of total protein were analyzed by Western blotting. A wild type strain (MAP5) that expresses 
Git1-V5, Git2-Myc, and Hsp90-GFP was subcultured in YEL 3% glucose o.n. to log phase and then sub-
cultured into a fresh YEL 3% glucose with the drug. After 16 h cells were harvested by TCA precipitation, 
and the western was performed. GA reduced Git1, Git2 and Gpa2 protein levels. As a control I used a Gpa2 
deletion. Note the intensity of the nonspecific band above Gpa2 did not change with increase in GA doses. 
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Figure 28. 
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Cells were collected before GA addition (0 time point) and after (15, 30, 60, and 90 
minutes) GA addition; cells were kept on ice and then harvested, and proteins were 
extracted between time points. By conducting immunoblot analyses against the 
endogenous Git1-V5, Git2-Myc and Actin we determined if their protein levels were 
affected by GA treatment. Unlike the obvious decline in Git1 and Git2 levels after long 
GA exposure (18 h) (Figure 28), brief exposure to GA (2 h) fails to reduce Git1 or Git2 
levels (Figure 29).  
 
To examine if Hsp90 is a part of the cAMP core complex, I examined the possibility that 
GA treatment of cells could alter cAMP levels after a brief exposure. Seeing an effect 
shortly after drug treatment would be a likely consequence of the cAMP complex falling 
apart. To test this hypothesis, FWP72 strain was grown in EMM complete overnight to 8 
X10 6 (cells/ml). The cultures were then treated with either a high dose of GA (10 µg/ml) 
or with an equivalent amount of DMSO as control. After two hours, cells were collected 
by filtration before, and 10 min after exposure to a final concentration of 100 mM 
glucose. Intracellular cAMP levels were immediately measured as previously described 
(BYRNE and HOFFMAN 1993) and by using a cAMP kit (Assay Designs). 
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Figure 29. The abundance of Git1 and Git2 was not affected by brief exposure of GA 
MAP5 were grown in YEL 3% glucose medium o.n. to early log phase. A high dose of GA (10 µg/ml) was 
added and cells were collected before GA addition (0 time point) and after 15, 30, 60, and 90 min after GA 
addition. Cells were immediately placed on ice and proteins were extracted between time points. A western 
blot was then performed against the endogenous Git1-V5, Git2-Myc and Actin. 
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Figure 29.   
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The results showed that the glucose-triggered cAMP response in the presence of GA 
were similar to that observed for cells treated with DMSO; they both respond to glucose 
exposure with almost four-fold increase in cAMP levels (Figure 30). Considered side by 
side, the cAMP experiment and immunblot analysis indicate that GA treatment does not 
rapidly alter protein stability or function of the cAMP pathway. 
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Figure 30. Cyclic AMP response to glucose in the presence of GA  
To examine the effect of brief exposure of GA treatment on cAMP signaling, we assayed the glucose-
triggered cAMP response after incubating the culture with GA for two hours. Cells were cultured overnight 
in EMM complete to log phase. Then, cells were either treated with DMSO or with (10 µg/ml) of GA. 
cAMP levels were immediately measured as previously described (BYRNE and HOFFMAN 1993) and by 
using by a cAMP kit (Assay Design) prior to glucose addition to the cultures, as well as 10 min after 
glucose addition to cultures either grown in the presence of DMSO or GA for 2 h. Both display a similar-
fold increase in cAMP levels after addition of glucose. 
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Figure 30. 
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SUMMARY AND FUTURE DIRECTIONS 
 
From yeast to mammals, Hsp90 and Sgt1 family proteins (including Git7) are highly 
conserved proteins, which function together as chaperones. In S. cerevisiae, the Hsp90 
and Sgt1 interaction is important for the formation of the CBF3 complex (LINGELBACH 
and KAPLAN 2004). In Arabidopsis thaliana, the Hsp90-Sgt1-RAR1 interaction is 
involved in forming the disease resistance complex (BOTER et al. 2007). This thesis is the 
first demonstration of Hsp90 and Git7 functioning together in S. pombe in the initial 
assembly of the cAMP signaling complex. In this section I will summarize and discuss 
findings from this thesis and propose a model for the role of Hsp90 and Git7 in cAMP 
pathway.  
 
5.1. Git10 encodes an Hsp90 protein involved in the cAMP pathway  
I have cloned git10, and shown that it encodes an Hsp90/Git10/Swo1 protein that acts in 
the S. pombe cAMP-signaling pathway. This pathway senses environmental glucose to  
repress transcription of genes involved in sexual development and gluconeogenesis, such 
as the fbp1+ gene (HOFFMAN 2005a; HOFFMAN 2005b). I found that attenuating Hsp90 
function either by mutation, pharmacological inhibition, or temperature stress impairs 
cAMP-mediated glucose signaling, consistent with a specific role for Hsp90 in the 
glucose/cAMP pathway.   
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Figure 31. Git10 in cAMP signaling pathway encodes an Hsp90 protein  
A new member of the cAMP pathway (Git10) was identified as an Hsp90 protein. The Git3 receptor detects 
glucose and transfers the signal to the Gα subunit that in turn activates Git2 adenylate cyclase, which 
produces cAMP. Three other proteins Git7, Git10/Hsp90, and the Git1 are also required for the activation 
of Git2. Hsp90 interacts with Git7 (Sgt1 homolog) and has a critical role in the cAMP/glucose signaling. 
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Figure 31.  
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A defect in cAMP signaling in a git10-201 mutant strain was previously demonstrated 
(BYRNE and HOFFMAN 1993), as was suppression of the fbp1+ regulatory defect by cAMP 
addition to the growth medium or by overexpression of the git2+/cyr1+ adenylate cyclase 
gene (HOFFMAN and WINSTON 1991).  Therefore, Hsp90 activity appears to be required 
for cells to detect glucose and activate adenylate cyclase.  
 
The hsp90+ is one of seven genes required for adenylate cyclase activation, which form at 
least two functionally-distinct groups as determined by the ability of mutations to be 
suppressed by the mutationally-activated Gpa2R176H Gα or by overexpression of the wild 
type Gpa2+ protein (LANDRY and HOFFMAN 2001; WELTON and HOFFMAN 2000).  
Increasing Gpa2 function bypasses the loss of the Git3 GPCR or Git5-Git11 Gβ Gγ, but 
not mutations affecting the Git1 C2-domain protein (KAO et al. 2006), the Git7 Sgt1-
family member protein (SCHADICK et al. 2002), or the Git10 Hsp90 protein.  
 
The central domain of Hsp90 appears to be a major site for client protein interactions 
(FONTANA et al. 2002; MEYER et al. 2003; SATO et al. 2000). Recent findings revealed 
this domain could also play a role in distinguishing between different types of client 
proteins (HAWLE et al. 2006). Therefore, the git10-201 L338P mutation in the central 
domain might impair client protein activity in the cAMP pathway specifically, whereas 
the temperature sensitive alleles swo1-21 which affects the N-terminal ATP-binding 
domain and swo1-26 which affects the C-terminal dimerization domain might cause a 
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universal impairment of Hsp90 function in the cell. Thus, git10-201 represents a 
separation-of-function allele of hsp90+, which confers a defect in cAMP signaling, but 
not other essential processes. A similar observation was reported in C. elegans in that loss 
of Hsp90/DAF-21 involved in cGMP signaling confers an early larval lethality; however, 
a missense mutation affecting a residue in the middle domain produces a viable adult 
with a chemosensory defect (BIRNBY et al. 2000). The daf-21 mutation allows C. elegans 
to enter the dauer larval form in the absence of temperature or nutritional stress signals 
similar to the S. pombe git10-201 mutation that allows mating and sporulation without the 
need of a starvation signal (Figure 13). Mapping of the residues altered by the da-f21 
mutation and by the git10-201 mutation onto the crystal structure of the S. cerevisiae 
Hsc82p central domain reveals that these two residues are in close proximity to each 
other (Figure 20).  Therefore, these two separation-of-function alleles may affect their 
individual cyclic nucleotide signaling pathways via the same mechanism.  
 
5.2. A novel link between glucose and heat sensing appears to involve Hsp90 
This thesis also revealed a new insight into heat stress in S. pombe. It has been long 
known that heat stress activates the Spc1/Sty1 SAPK pathway required for fbp1+ 
transcription, presumably by regulating the activity of the Pyp1 tyrosine phosphatase 
(SAMEJIMA et al. 1997). Data from this thesis further indicate that in addition to 
activating the SAPK pathway, heat stress reduces PKA activity. Stresses such as nitrogen 
starvation and osmotic stress, which activate the SAPK pathway, do not derepress fbp1+ 
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transcription (DEVOTI et al. 1991; JANOO et al. 2001; STETTLER et al. 1996; STIEFEL et 
al. 2004; YANG et al. 2003), indicating that reduction of PKA activity is required for 
fbp1+ derepression. Therefore, I have discovered a novel link between glucose and heat 
sensing that appears to involve Hsp90. Heat stress may redirect Hsp90 from acting in the 
cAMP pathway to acting upon targets that are critical to survival of heat stress (Figure 
32).  As a secondary effect, the ability of heat stress to reduce PKA activity and thus 
mimic glucose starvation may assist in producing a growth arrest that enhances cell 
survival at elevated temperatures. Greater insight into the relationship between heat stress 
and glucose signaling might be gained by studying glucose triggered cAMP signaling by 
assaying cAMP levels. Heat stress might alter the formation of the cAMP complex that is 
required for glucose repression. Comparing the cAMP complex composition (Git2-Git1 
complex) purified under starvation conditions (nutrition stress) and purified under 
elevated temperature (heat stress) could also provide new insights. Another avenue of 
research would test whether Hsp90 is required for the localization of any of the cAMP 
complex proteins (Gpa2, Git1, and Git2) to either the plasma membrane or to punctate 
structures in the cytoplasm. This can be accomplished easily by immunofluorescence 
using geldanamycin or heat stress, which might induce the delocalization of these 
proteins. 
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Figure 32. Stress may redirect Hsp90 from acting in the cAMP pathway to acting upon targets that 
are critical to survival of heat stress.  
(A) Hsp90 is involved in different processes in the cell including the cAMP signaling discovered in this 
thesis. (B) Heat stress might lead to accumulation of misfolded proteins might titer away Hsp90 from 
cAMP resulting in the release of fbp1 transcription under repression conditions.  
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Figure 32.  
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 127 
5.3. Hsp90 and Git7 transiently interact in S. pombe 
Human, S. cerevisiae, and Arabidopsis thaliana Hsp90 proteins have been shown to 
interact with the Sgt1 protein (homologous to Git7), which appears to function as a co-
chaperone to Hsp90. Sgt1 recruits specific clients to Hsp90 and aids in the transient 
assembly of protein complexes (CATLETT and KAPLAN 2006);(LINGELBACH and KAPLAN 
2004; TAKAHASHI et al. 2003). In S cerevisiae, this interaction is essential for the 
formation of the CBF3 (LINGELBACH and KAPLAN 2004). In Arabidopsis thaliana, the 
Hsp90-Sgt1-RAR1 interaction is involved in forming the disease resistance complex 
(BOTER et al. 2007). Both Sgt1 and Hsp90 are highly conserved in eukaryotes; thus, this 
chaperone co-chaperone interaction might be conserved from yeast to humans. 
 
Findings that Sgt1 interacts with Hsp90 in other systems and the demonstration that git7 
mutants are geldanamycin supersensitive (Chapter 4) led me test whether Git7 and Hsp90 
form a co-chaperone complex in S. pombe. Experiments revealed an interaction between 
Git7 and Hsp90 in S. pombe. Surprisingly, mutations in both git7 and git10/swo1 act to 
strengthen this interaction (Figure 24). These mutations might change the conformation 
of the proteins, and therefore could stabilize a transient interaction. This result indicates 
that the Hsp90-Git7 interaction must remain transient for the complex to function 
properly. 
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Other research has also indicated that Hsp90 transient interactions can be stabilized by 
mutations in interacting proteins. A study by Piper al et. 2004 showed that many Hsp90 
interactions with other proteins are transient, preventing an analysis of these associations 
by the two-hybrid system. However, they demonstrated that these Hsp90/Hsp82 
interactions could be stabilized in vivo by using an Hsp90/Hsp82 mutation that inhibits 
the ATP hydrolysis step of the Hsp90 chaperone cycle (MILLSON et al. 2005). Similarly, 
the Sgt1 interaction with Hsp90 and Skp1 in S. cerevisiae is stabilized by a mutation 
affecting the C-terminus of Sgt1 designated as sgt1-5, disrupting CBF3 assembly and 
affecting cell growth (LINGELBACH and KAPLAN 2004). Thus, it is evident that the 
transient interaction between Hsp90 and its Sgt1/Git7 co-chaperone is critical to the 
function of this complex.  
 
Observations in this thesis do not address whether the Git7-Hsp90 interaction is direct but 
could represent that they are in the same complex. Additional proteins might be required 
to mediate the Git7-Hsp90 interaction. This can be investigated by using yeast two-
hybrid to test these interactions. Further studies are also needed to determine which 
domains in Git7 and Git10/Hsp90 are involved in the interaction. In addition, different 
conformational states of Hsp90 (Hsp90-ADP open structure /Hsp90-ATP closed 
structure) might have an effect on the nature of these interactions. This can be tested by 
performing Hsp90-Git7 co-immunoprecipitation in wt and different git mutants and 
git10-201 in the presence of geldanamycin (to lock Hsp90 in the ADP–bound 
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conformation) or molybdate  (to lock Hsp90 in the ATP–bound conformation) and assess 
the effect of these different conditions on Git1-Git2 interaction.  
 
5.4. Git7 is an Hsp90 co-chaperone 
As mentioned above, Sgt1 is involved in kinetochore assembly, cAMP signaling, and 
disease resistance in different organisms. Results from our lab revealed that although 
Git7 protein is essential, it does not appear to be involved in kinetochore function in S. 
pombe. Deletion of git7 is lethal, thus indicating its involvement in cellular processes 
other than cAMP signaling, which is not essential for cell viability in S. pombe 
(SCHADICK et al. 2002).  The presences of three git7 glucose insensitive mutations (git7-
235, git7-27, and git7-93) were informative in studying its function in S. pombe (Figure 
33). The git7-235 and git7-27 mutations confer defects in cell wall integrity and septation 
as well cAMP signaling, but git7-93 confers only a cAMP defect. Therefore, mutations 
affecting either the N-terminal (TPR domain) or in the highly conserved C-terminus 
(SGS domain) disrupt cAMP signaling. However, the N-terminus of Git7 serves another 
function in addition to a role in cAMP signaling. Figure 33 summarizes phenotypes 
associated with git7 mutants in S. pombe.  
 
After Git10 was identified as Hsp90, we significantly advanced our understanding of the 
function of Git7 in S. pombe. As discussed above, I was able to show that Hsp90 co-
immunoprecipitates with the Git7 in S. pombe. However, these observations alone do not 
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demonstrate that Git7 is an Hsp90 co-chaperone.  
 
Findings from other researchers indicating that Hsp90 and Sgt1 interact in various 
pathways in different organisms have assisted my exploration of Hsp90 function in S. 
pombe. A mutation in git7 or in hsp90 causes elevated levels of fbp1 transcription 
(HOFFMAN and WINSTON 1990; HOFFMAN and WINSTON 1991). Hence, both Git7 and 
Hsp90 are important in proper cAMP signaling in S. pombe. Abrogating Hsp90 function 
using a pharmacological approach confirmed the genetic data. Furthermore I found that 
temperature-sensitive Git7 mutants (git7-27 and git7-235) display GA super sensitivity at 
the permissive temperature. Schadick et al.2002 showed that that git7 temperature-
sensitive mutants develop cytokinetic defects when they are incubated at the restrictive 
temperature. Therefore, I used geldanamycin to test whether the previous cytokinetic 
defect observed in git7 mutants at elevated temperature was specific to Hsp90 function 
with Git7. Consistent with Schadick et al.2002 findings, this analysis revealed that 
Geldanamycin-treated git7 mutants (git7-27 and git7-235) exhibit similar deleterious 
cytokinesis defects (Figure 25,33). Remarkably, git7-93 and a git2 deletion show no 
cytokinesis defect in the presence of geldanamycin although they both displayed severe 
defects in cAMP signaling, demonstrating that the cytokinesis is not due to the defect in 
cAMP signaling.  
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Figure 33. Schematic of Git7 protein structure   
Schematic of the Git7 protein structure showing the three domains: TRP, CS, and SGS and the phenotypes 
associated with git7 mutants in S. pombe presented in this thesis. A star represents a mutation.   
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Figure 33. 
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Recently, it was reported that Hsp90 has a role in assembling the myosin II complex, 
which is important for forming the actomyosin ring involved in cytokinesis (MISHRA et 
al. 2005). The git7 mutants show phenotypic similarities to hsp90, myo2, and rng3 
mutants. The multinucleated phenotypes of the S. pombe git7 alleles git7-235 and git7-27 
suggest that the git7 mutants might also be defective in actomyosin ring assembly as seen 
with hsp90, myo2, and rng3 mutants. Therefore, Git7 in addition to Hsp90 and Rng3 
might assist in proper Myo2p function in the fission yeast S. pombe.  
 
Temperature, pharmacological, and western analyses in this thesis suggest that Hsp90 
and Git7 function in tandem in S. pombe. Git7 with Hsp90 can help in forming at least 
two complexes. Given that git7-27 and git7-235 mutant alleles confer both morphological 
defects and cAMP signaling phenotypes similar to those of the swo1- mutant alleles, it 
suggests that Hsp90 and Git7 work in partnership in at least two different processes, cell 
division and in cAMP signaling. Furthermore, the presence of the separation-of-function 
alleles, git7-93 and git10-201, implies that these proteins act on a specific client protein 
or on the assembly of a protein complex acting in the cAMP pathway and argues against 
a model in which mutations that impair Git7 and/or Hsp90 activity simply create a 
general stress that mimics a glucose-starvation signal. The focus should remain on 
investigating their roles in cAMP, not their role in other processes, which can be 
tempting. Focusing on git7-93 and gi10-201 alleles, both of which confer defects in 
cAMP but do not affect essential process, would be appropriate to restrict studies to 
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cAMP signaling. In addition, mutations in the git7 middle domain would be worth 
investigating since little is known about this domain. 
 
5.5. A model of the roles of Hsp90 and Git7 function in the cAMP pathway  
Hsp90 and Sgt1/Git7 maintain the activity of a number of cellular proteins that are 
involved in signal transduction. It is proposed that Hsp90 and its co-chaperone Sgt1 act in 
signal transduction by assisting in complex formation. The downstream effector of Git7 
and Hsp90 in the S. pombe cAMP signaling pathway is still unclear. In S. cerevisiae, 
Dubacq et al.2002 demonstrated that cAMP activity was affected by the sgt1-5 mutation. 
In addition, they showed that Sgt1 physically interacts with adenylate cyclase 
(Cyr1/Cdc35) although this is only detected when the two proteins are over-expressed. In 
S. pombe, Hsp90 and Git7 are both required even in a strain carrying an activated gpa2 
allele. Therefore Hsp90 and Git7 may be required for stabilization of Gpa2 or adenylate 
cyclase, or for efficient coupling of Gpa2 to adenylate cyclase. 
 
The Hsp90 machinery appears to regulate signaling pathways in cells by one of two 
mechanisms: in some cases it appears to stabilize client proteins; in others it functions in 
the assembly of protein complexes. In order to understand the role of Hsp90 in cAMP 
pathway, I tested three models (Figure 34). The first model suggests the involvement of 
Hsp90 in the stabilization of key players in cAMP pathway. The second model is that 
Hsp90 is a permanent structural component of the cAMP complex. Finally, the third 
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model is that Hsp90 is involved in the assembly of cAMP complex (Git2-Git1-Cap-
Actin) (Figure 34). 
 
To test the first model, I performed a time point experiment where brief exposure of GA 
to cells (2 h) demonstrated no change in Git1 and Git2 abundance (Figure 29). This 
indicates that Hsp90 does not stabilize Git1 or Git2 in the cAMP pathway.  
 
To test the second model, I showed that cells treated with GA for 2 h were still able to 
produce cAMP signal in response to glucose addition (Figure 30). If Hsp90 is a 
permanent component of the cAMP pathway, I would have expected GA treatment to 
produce rapid loss in signaling. Therefore, my data indicate that Hsp90 is not part of the 
core Git1-Git2 cAMP complex.  
 
To test the third model, I showed that GA treatment significantly reduced Git2, Git1, and 
Gpa2 protein levels after a long period of drug exposure (18 h) (Figure 28). This delay in 
cAMP defects suggests that Hsp90 is not a core component of the cAMP complex but is 
required for the complex assembly. These results might also imply that compromising 
Hsp90 function by GA only destabilized the newly synthesized Git2, Git1, Gpa2 (the free 
forms), but did not affect the pre-existing assembled complexes. 
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Figure 34. Three models proposed to test the function of Hsp90 in cAMP pathway 
Geldanamycin (GA) is a drug that binds the N-terminal ATP-binding site of Hsp90 and will lock Hsp90 
into the inactive form (ADP form). This will result in inhibiting Hsp90 normal function and subjecting its 
targets to degradation. Therefore, this drug has been used in this thesis to test the three proposed models to 
investigate Hsp90 role in cAMP signaling. (A) The first model suggests the involvement of Hsp90 in the 
stabilization of key players in cAMP pathway. (B) The second model suggests that Hsp90 is a permanent 
structural component of the cAMP complex. (C) The third model suggests that Hsp90 is involved in the 
assembly of the cAMP complex. 
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Figure 34. 
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Previous findings in our lab have shown that adenylate cyclase (Git2) forms a complex 
with Git1 by co-immunoprecipitation (KAO et al. 2006) and that TAP tag purification 
(Wang ,unpublished data) of Git1 and Git2 in a wild type strain did not show the 
association of Git7 with Hsp90 (Figure 35A). However, it maybe that Hsp90 and Git7 
work together in an initial step to aid in Git-Git2 complex formation and that this 
interaction is transient to detect in a TAP tag experiment. We hypothesized that if this 
were the case, we might observe loss of Git1-Git2 interaction in a Git7 or Hsp90 mutant 
background. To test this hypothesis I performed TAP purification in two mutant 
backgrounds: git10-201 and git7-235. Git2-TAP tag purifications in these strains were 
not successful (data not shown). However, TAP tag purifications of Git2-TAP in strains 
carrying git7-93 mutation and git2-7 were successful (Wang, unpublished data). The 
Git1-Git2 interaction was lost in these mutants background and interestingly, Hsp90 was 
also found with Git2-TAP.  
 
Findings from git7-93 and git2-7 Git2 TAP tag purifications suggest that Git7, an Hsp90 
co-chaperone, is not a core component of the cAMP complex but a critical element for 
maintaining the Git1 and Git2 interaction, since the absence of functional Git7 protein 
resulted in a defect in complex assembly. Furthermore, Hsp90 detection with Git2-TAP 
in git2 and git7 mutant backgrounds supports the idea that Hsp90 is not a regular 
component of the active core complex but rather assists in assembly process. This 
abnormally stable interaction of Hsp90 with Git2 might prevent Git1 assembly with Git2 
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or might freeze the complex in an inactive state due to a defect in a component in the 
signaling pathway (Figure 35 B,C).  
 
Consistent with this role for Hsp90-Git7, analyses of the cAMP response and of Git1, 
Git2, and Gpa2 levels after exposure to GA demonstrate that the effect of GA is not 
immediate loss of protein stability or cAMP signaling. In addition, unlike the core 
components of cAMP complex Git1 and Git2, Hsp90 and Git7 proteins levels are not 
regulated by glucose conditions; even though a mutation in either gene can result in fbp1-
derepression. This further supports the idea that Hsp90 and Git7 are not core members of 
the cAMP complex but are required in the complex assembly.  
 
Therefore, on the basis of the research performed for this thesis and other findings from 
our laboratory I propose a model where Git7 and Hsp90 form a co-chaperone complex 
and probably function together as an initial step to aid in Git1-Git2-Cap-Actin complex 
formation (Figure 31,35A). 
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Figure 35. Git7 and Git10/Hsp90 are required for the assembly of the cAMP complex  
Schematic diagram showing the composition of the cAMP complex by using TAP and mass spectrometry 
analysis in different strain backgrounds. The Git2-Git1 interaction is lost in git7-93 and git2-7 mutants. 
Defective Git2-complexes contain Hsp90 in git7-93 and git2-7. Incorporating the current findings from our 
lab in addition to the new data presented here support the idea that Git7 and Hsp90 are required for the 
assembly of the cAMP complex but are not permanent structural components of the active complex.  
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Figure 35.  
 
 
 
A.     B.     C.  
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To further understand the role of Hsp90-Git7 in cAMP complex formation, an 
immunoprecipitation and western analysis will be useful to check the presence of both 
Hsp90 and Git7 in Git2-Git1 complexes in different mutant backgrounds (git7-235, git7-
93, git7-27, git10-201, swo1-21, swo1-26, and git2-7) and under different glucose 
conditions. Hsp90 and possibly Git7 might be also present in Git2 immunoprecipitates in 
some of these mutant backgrounds. These results might show that Hsp90 and Git7 bind to 
Git2 prior to complex assembly and that their presence with cyclase prevents Git1 from 
binding Git2. In addition, Hsp90 might be absent or reduced from the adenylate cyclase 
complex under conditions where the complex should be functional and active.  
 
How does the co-chaperone complex (Hsp90-Git7) function to activate the Git1-Git2 
complex in cAMP/glucose signaling pathway? Future studies could focus on the regions 
of Git1 and Git2 that interact with each other, as well with the Hsp90-Git7 complex. 
Findings from fission yeast will provide an additional regulatory mechanism of this co-
chaperone complex that will contribute to a better understanding of their functions in 
other organisms.  
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APPENDIX ONE 
THE DISCOVERY OF NOVEL HUMAN PDE7A 
INHIBITORS USING YEAST AS A CELL-BASED SYSTEM 
FOR HIGH THROUGHPUT SCREENING 
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1. INTRODUCTION  
 
1.1. Cyclic AMP  
Cyclic AMP is synthesized from adenosine triphosphate (ATP) by adenylate cyclase and 
is degraded by cAMP phosphodiesterase. Cyclic AMP activates protein kinase A (PKA), 
which consists of two catalytic and two regulatory subunits. It binds the regulatory 
subunits of a protein kinase, and this causes the dissociation of the regulatory and 
catalytic subunits resulting in the activation of the catalytic subunits. Concentration of 
cAMP in the cell is critical. Any change in this process can result in aberrant cell 
behavior. For example, impaired cAMP signaling may contribute to the pathophysiology 
of cardiovascular, neurological, metabolic and inflammatory disorders (CAI et al. 2001; 
MOORE and WILLOUGHBY 1995; MOVSESIAN and BRISTOW 2005).  
 
1.2. Phosphodiesterases  
Phosphodiesterases (PDEs) are enzymes that hydrolyze the cyclic nucleotide second 
messengers, cAMP and cGMP. There are 21 genes that encode 11 families of mammalian 
PDEs. There are PDEs which are cAMP-specific enzymes (PDE4, PDE7, PDE8), cGMP-
specific (PDE5, PDE6, PDE9) and also PDEs, which can act on both cAMP and cGMP 
(PDE1, PDE2, PDE3, PDE10, and PDE11). Chemical inhibitors of PDEs are potential 
therapeutic compounds for the treatment of a variety of diseases including Alzheimer’s 
Disease, Parkinson’s Disease, Huntington’s Disease, schizophrenia, asthma, pulmonary 
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disease, hypertension, stroke, rhinitis, chronic lymphocytic leukemia, prostate cancer, 
thyroid disease, cardiac disease, multiple sclerosis, rheumatoid arthritis, penile erectile 
dysfunction and depression. PDE enzymes are good targets for pharmacological 
inhibition due to their unique tissue distribution, structural and functional properties. 
 
1.3. PDE7 
PDE7 is a cAMP specific family. There are two PDE7 genes, PDE7A (has three splicing 
variants A1, A2, A3) and PDE7B (has three splicing variants B1, B2, B3). Both PDE7A 
and PDE 7B show 70% catalytic domain homology. PDE7 is sensitive to the nonselective 
PDE inhibitor IBMX (Figure 1) and resistant to rolipram, a PDE4 selective drug.  
 
1.4. PDE7A  
Expression of PDE7A1 RNA has been detected in pancreas, lung, spleen, testis, brain, B 
cells and in CD4+ and CD8+ T cells. It has been shown that PDE7A is upregulated in 
CD4+ T cells, and that inhibition of PDE7A up-regulation with an antisense oligo leads to 
inhibition of cell proliferation, suggesting PDE7A involvement in the regulation of T cell 
proliferation (LI et al. 1999).  
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Figure 1. Human PDE7A binding to IBMX  
PDE7A (1zkl) ribbon and surface structure showing the location of IBMX binding (Black color). The 
graphic image was created using Pymol (DeLano Scientific) and by MBT protein workshop (MORELAND et 
al. 2005) available on the PDB website. Human PDE7A crystal structure data was obtained from (WANG et 
al. 2005a). 
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Figure 1. 
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1.5. Using Schizosaccharomyces pombe to screen for PDE inhibitors  
Since cAMP signaling is present in simpler single cell organisms such as fission yeast, 
these cells serve as a convenient model for studying these complex pathways. The fission 
yeast Schizosaccharomyces pombe monitors glucose to regulate a wide range of 
biological processes such as sexual development and metabolism.  
 
Our lab (Hoffman lab, Boston College) has a history in studies regarding glucose –
mediated transcriptional regulation identifying mutations in genes that confer constitutive 
fbp1+ transcription, by using two reporters fbp1-ura4 and fbp1-lacZ (VASSAROTTI and 
FRIESEN 1985); (HOFFMAN and WINSTON 1990). These genes are called the glucose 
insensitive transcription (git) genes (HOFFMAN 2005b). One of the genes is git2+/cyr1+ 
which encodes adenylate cyclase (HOFFMAN and WINSTON 1991). The function of 
adenylate cyclase is to produce the second messenger cAMP from ATP in order to 
activate PKA. Additional git genes are required for adenylate cyclase activation. Four 
genes encode the Git3 G protein-coupled receptor (WELTON and HOFFMAN 2000) and its 
cognate heterotrimeric G protein composed of the Gpa2, Gα (ISSHIKI et al. 1992; 
NOCERO et al. 1994), the Git5 Gβ (LANDRY et al. 2000), and the Git11 Gγ (LANDRY and 
HOFFMAN 2001). Mutations in any of these genes result in the reduction of cAMP levels, 
and confer constitutive fbp1+ transcription which will result in a Ura+ /5FOAs phenotype 
(Figure 2A). Therefore, this system can be used to screen for PDE inhibitors, since a PDE 
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inhibitor should restore 5FOAR growth by elevating cAMP levels to repress fbp1-ura4 
transcription (Figure 2B).  
 
1.6. Focus of research  
The recent identification of PDE7-specific inhibitor (BRL 50481) demonstrates the 
importance of PDE7 inhibition in the treatment of inflammatory illnesses. BRL 50481 
was able to block TNF secretion and inhibit T cell proliferation in a dose-dependent 
manner (LERNER and EPSTEIN 2006; SMITH et al. 2004). Therefore the discovery of more 
PDE7A inhibitors is necessary to develop successful drugs that have the potential for 
treating anti-inflammatory disorders.  
 
The power of this research is using S. pombe to develop in vivo assay to screen for 
inhibitors of Human PDE7A. This has been accomplished by replacing the S. pombe PDE 
with human PDE7A, in the presence of either the git3 or gpa2 mutation. This reduced 
cAMP levels, and consequently conferred a 5FOA-sensitive (5FOAS) phenotype. In the 
presence of PDE7A inhibitor, cells should restore 5FOAR growth by elevating cAMP 
levels to repress fbp1-ura4 transcription. I will describe herein human PDE7A integration 
and the strain optimization process. Using it I was able to discover novel specific PDE7A 
inhibitors and show their direct effect on cAMP levels.  
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Figure 2. cAMP pathway in S. pombe  
(A) Mutations in genes involved in glucose –mediated transcriptional regulation confer constitutive fbp1+ 
transcription. These genes are called the glucose insensitive transcription (git) genes. (AC) is git2+/cyr1+, 
which encodes adenylate cyclase that produces the second messenger cAMP from ATP to activate PKA. 
Additional git genes are required for (AC) activation. Four genes encode the Git3 G protein-coupled 
receptor and its cognate heterotrimeric G protein composed of the Gpa2 (Gα, Gitγ, Gβ). Mutations in any 
of these genes result in lowering cAMP levels, and confer constitutive fbp1+ transcription which will result 
in a Ura + /5FOA s phenotype. 
(B) Phosphodiesterase (PDE) is the enzymes that hydrolyze the cyclic nucleotide second messengers, 
cAMP. In the presence of a PDE inhibitors cAMP levels should get elevated and repress fbp1-ura4 
transcription that will restore 5FOAR growth.  
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Figure 2.  
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2. Materials and Methods  
 
2.1. Growth Medium  
Yeast were grown and maintained using several types of media. Yeast extract agar (YEA) 
for plates, yeast extract liquid YEL for gene transformation (GUTZ et al. 1974), defined 
medium EMM (Biochemicals) were supplemented with required nutrients at 75 mg/L, 
except for L-leucine, which was at 150 mg/liter, and 2.5 mM cAMP was used for pre-
growth for screening purposes. SC liquid or solid medium containing 0.4 g/L 5-fluoro-
orotic acid (5FOA) and 8% glucose were used for screening, as previously described 
(HOFFMAN and WINSTON 1990).  
 
2.2. Yeast  
Yeast strains used in this study are two strains carried the fbp1::ura4+ and ura4::fbp1-
lacZ reporters (Table 1). Both are translational fusions integrated at the fbp1+ and ura4+ 
loci, respectively, as described by Hoffman and Winston (HOFFMAN and WINSTON 1990). 
Strains were grown at 30°C unless indicated otherwise. 
 
2.3. Strain mating and tetrad dissection  
Mating was performed on malt-extract agar (MEA) for 24 to 48 h at 30°C. In the case of 
homothalic strains, they were pre-grown at 37°C prior to mating. Asci formed on MEA 
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were transferred using a dissection needle to a YEA 3% glucose rich plate. Zygotic asci 
that were selected were then incubated at 37°C for at least 2 h to facilitate the breakage of 
the cell wall and the release of the spores. Tetrads were then dissected and plates were 
subsequently incubated at 30°C for 3 days and then scored.  
 
2.4. β-galactosidase assays of fbp1-lacZ expression  
Cells were grown under repressing conditions (8% glucose) in yeast extract at the 
indicated temperatures (YEL). Subcultures were grown to exponential phase until 
reaching a density of 1 x 107 cells/ml. Soluble protein extracts were prepared by glass 
beads in breaking buffer (0.1 M Tris pH 8, 20% glycerol, 1 mM DTT) and PSMF (40 
mM). The assay was performed using Z buffer, made as described in current protocol in 
molecular biology. Ortho-Nitrophenyl-β-galactoside (ONPG) was used to start the 
reaction and Na2CO3 (1 M) solution was used to stop the reaction when yellow color 
started to develop. Samples were read at OD420 for each sample. Total soluble protein was 
measured by BCA assay (Pierce Chemical Co). 
 
2.5. PDE7A sequencing 
PDE7A was PCR amplified from a plasmid clone obtained from the Beavo lab and the 
ends of the PCR product were sequenced using custom oligonucleotides (Integrated DNA 
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Technologies). DNA sequencing was performed using the CEQ DTCS-Quick Start kit 
(Beckman Coulter).  
 
2.6. PCR   
Human PDE7A was amplified using primers that were designed according to deduction 
by using the sequencing results. A high fidelity enzyme, Herculase, was used for 
amplification according to the manufacturer’s instructions. Colony PCR was performed 
to screen for positive integrants by using Taq polymerase. 
 
2.7. Cyclic AMP and protein extraction 
Cells treated with a drug or DMSO were collected by air vacuum into a micropore glass 
filter (Fisher). Filters were then submerged into 1 ml of 1 M formic acid and vortexed for 
30 s to break the cell walls. Filters were removed and the samples centrifuged for 10 min 
at 14000 x g. 400 ml of supernatant was lyophilized using a speed vacuum for 4 h 
(BYRNE and HOFFMAN 1993). Finally, the pellets were resuspended in 80 ml 0.1 HCl. 
Assay was performed using cAMP Direct kit (Assay Designs). Proteins from the same 
samples were extracted by resuspending the cells in 0.2 N NaOH with 0.4 g of glass 
beads. The tubes were then vortexed for 3 min to break the cells. The samples were 
boiled for 3 min followed by centrifugation for at 14,000 x g for 2 min to remove cell 
debris. Protein quantification was performed using a BCA kit.  
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2.8. PDE7A transformation and screen for positive integration  
Cells were grown in YEL overnight to early log phase 5 x 106 cells/ml. Then cells were 
pelleted and washed twice with cold water and buffer (LiAc/TE). Pellets were 
resuspended in 100 ml LiAc/TE and mixed with 1 ml boiled salmon testes DNA and 10 
ml of concentrated PDE7A DNA (8 samples were combined and ethanol precipitated 
then dissolved in 10 ml of dH20). The samples were kept for 10 min at room temperature 
before adding 260 ml of (40% PEG, 100 mM LiOAc, 10 mM Tris-HCl pH 7.5) buffer. 
Samples were then incubated at 30˚ C for 1 h, then were heat shocked for 5 min at 42˚C 
after adding 43 ml of DMSO to each sample. The cells were grown in 3% YEL for 20 h 
for recovery. Finally, cells in different dilutions were plated on the 5FOA medium 
(BÄHLER et al. 1998). Colonies were screened for positives (PDE7A integrated colonies) 
after 6-8 d post gene transformation. Plates were inverted over iodine vapors for 5 min. 
Positive colonies that carry active PDE7A in them stain dark brown by iodine vapor. The 
amount of staining reflects the sporulation frequency. Sporulation was also confirmed 
microscopically. Positive colonies were streaked on fresh YEA medium and PCR 
analysis confirmed the presence of PDE7A in S. pombe (See Results). 
 
2.9. Microscopy  
The DIC Images of cells were captured using a Zeiss microscope with an Orca-ER CCD 
camera. The microscope – camera are connected to a computer that is equipped with 
Openlab software. 
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2.10. Screening process  
High throughput drug screens were performed at the Broad Institute’s Chemical Biology 
Program screening facility. Figure 3A summarizes the screening process. PDE7A 
cultures (CHP1189) were pre-grown in EMM complete medium, containing 2.5 mM 
cAMP for overnight growth. Cells were washed, mixed very well, then transferred to 
384-well microtiter dishes into 5FOA medium at a final density 1 x 105 cells/ml and a 
final volume of 50 ml. 100 nl of compounds were pinned to the bottom of the wells at a 
final concentration of 20 µM. Control plates received 100 nl DMSO. Positive control 
plates had 5mM cAMP added in the 5FOA medium. Cultures were incubated for 48 h at 
30ºC, and sealed in a container with moist paper towels to prevent evaporation. Optical 
density (OD600) of cultures was measured after mixing the cells with a plate mixer. 
Positive Hits should show a high OD reading that can be even visible by eye, as seen in 
the case of one of the PDE7A inhibitors (Figure 3B).  
 
2.11. Bioinformatics  
Files from the Optical density (OD600) readings were sent to the Bioinformatics team at 
the Broad institute in order to determine the CompositeZ scores. Hits were visualized and 
analyzed in the lab by using the Spotfire software (Spotfire, Inc., Somerville, MA).  
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Figure 3. PDE7A screening process  
(A) This figure summarizes the screening process. 25ml of 5FOA medium was delivered to a 384-well 
microtiter plate. 100 nl of compounds were pinned into the wells to a final concentration of 20 mM. 
Control plates received 100 nl DMSO. (CHP1189) PDE7A expressing cells were then washed, mixed very 
well, and transferred to the prepared plates at a final density of 1 x 105 cells/ml and a final volume of 50 ml 
of 5FOA medium. Plates were stacked and incubated for 48 h at 30ºC, sealed in a container with moist 
paper towels to prevent evaporation. Optical density (OD600) of cultures was measured after mixing the 
cells with a plate mixer. (B) “Hits” can be visible by eye as seen in the case of one of PDE7A inhibitors. 
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Figure 3. 
A. 
 
B. 
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3. RESULTS  
3.1. Construction of strains that express human PDE7A  
I integrated human PDE7A in S. pombe by replacing the cgs2+ gene (S. pombe PDE) with 
the PDE7A gene using homologous recombination. To accomplish this, PDE7A was 
amplified by PCR using primers that create product with PDE7A copies with flanking 
cgs2 sequence for direct integration (Figure 4). The PCR product was then transformed 
into a cgs∆::ura4+ strain (JZ666), using a DMSO transformation protocol. Cells were 
grown in YEA3% glucose as a recovery period, then were plated on 5FOA (5FOA is 
being used for counter-selection) to identify and distinguish candidates that express the 
human PDE7A, from the cgs2 locus.  
 
A strain that carries an active PDE should be able to sporulate under starvation 
conditions, as seen in (Figure 5) with PDE7A integrants. Positive colonies were streaked 
onto fresh YEA medium and PCR analysis confirmed the presence of PDE7A in S. 
pombe. (See Materials and Methods for details in screening for positives). 
Finally, crosses were performed to construct strains that contained the PDE7A construct 
with fbp1-ura4 and fbp1-lacz reporters along with either the gpa2 Gα subunit mutation or 
git3 glucose receptor mutation, both of which are required for glucose detection, 
adenylate cyclase activation, and transcriptional repression of the fbp1 gene.  
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Figure 4. Human PDE7A integration process to S.pombe  
Human PDE7A integration into S. pombe by replacing the cgs2+ gene (S. pombe PDE) with the PDE7A 
gene using homologous recombination. PDE7A was amplified by PCR using primers that create PDE7A 
copies with flanking cgs2 sequence for direct integration.  
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Figure 4. 
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Figure 5. Human PDE7A integrants are able sporulate under starvation conditions  
PDE7A integrants were able to sporulate under starvation a condition, which indicates the presence of an 
active PDE. 
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Figure 5. 
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The expression level of ura4 and lacZ reporters in these strains reflects the activity level 
of PDE7A. β-galactosidase activity in these strains, demonstrate PDE7A was active 
compared to a strain expressing defective truncated PDE (Cgs2-2) (data not shown). 
 
Introducing a defect in cAMP (git3/gpa2) will confer 5FOA sensitive phenotype by 
reducing cAMP production. Therefore, this strain can be used to screen for PDE7A 
inhibitors. In the presence of an inhibitor, PDE7A activity will be reduced elevating 
cAMP levels. As a result,  fbp1- ura4 expression will be repressed, which will then result 
in 5FOA resistant growth  (Figure 6).  
 
3.2. PDE7A optimization 
To determine the best conditions for high throughput drug screening, a number of factors 
need to be taken into consideration including the right genetic background, the right 
cAMP concentration for pre-growth conditions, and final cell densities, all important 
elements in the optimization process. As a first test, strain CHP1169 expressing PDE7A 
in the git3 deletion background was pre-grown in EMM medium containing different 
concentrations (0, 0.5, 1, 1.5, 2.5) mM of cAMP and different final cell densities (0.5 x 
105, 1 x 105, 4 x 105, then cultures were transferred to 5FOA in the presence or absence 
of 5 mM cAMP. The OD600 measurements were taken after 48 h of incubation at 30ºC 
(cells were grown in the presence of cAMP in order to repress the fbp1-ura4 reporter 
prior to exposure to 5FOA medium). 
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Figure 6. PDE inhibitors screening concept  
(A) S. pombe PDE replaced with human PDE7A, in the presence of either the git3 or gpa2 mutation, which 
will result in the reduction in cAMP levels, should confer a 5FOA-sensitive (5FOAS) phenotype. (B) In the 
presence of a PDE7A inhibitor cells should restore 5FOAR growth by elevating cAMP levels to repress 
fbp1-ura4 transcription.  
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Figure 6. 
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I found that the best conditions were when the strain was pre-grown in EMM with 2.5 
mM of cAMP and by using 1 x 105 as final cell density when transferred to 5FOA. I also 
found that the PDE7A doubling time was 3.5 - 3.7 h. Testing the strain CHP1169 
(PDE7A) in git3 deletion background in the lab in a 96-well plate gave an OD600 of 0.93 
+/- 0.05 in wells where cAMP was added to the cultures, while an OD600 of 0.07 +/- 0.01 
was observed for wells where cAMP was not added (Figure 7). 
 
To further test the best genetic background for high throughput drug screening, strains 
CHP1169 expressing PDE7A in a git3 deletion background and the strain CHP1189 
expressing PDE7A in a gpa2 deletion background were pre-grown in EMM medium 
containing 2.5 mM cAMP and then transferred to 5FOA medium in 384-well microtiter 
plates in the presence 5mM of cAMP (representing the positives), or the absence of 
cAMP (representing the negatives). OD600 measurements were taken after 48 h of 
incubation at 30ºC. In each strain, the addition of cAMP restored 5FOAR growth. In 
strain CHP1169, the OD600 of the cultures +cAMP was 1.45 +/- 0.074, while the OD600 of 
the cultures –cAMP was 0.61+/- 0.05 when the final density was 1x105. When using 
strain CHP1189 , the OD600 of the cultures +cAMP was 1.31 +/- 0.03, while the OD600 of 
the –cAMP cultures was 0.060+/- 0.01 when the final density was 1x105. The Z factors 
for these screens were 0.65 and 0.91, respectively. The Z factor is a statistical assessment 
of the quality of datasets used in high throughput screening. A strain should have a Z 
factor above the value 0.5 in order to qualify for screening (Figure 8). 
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Figure 7. Optimization conditions of strain CHP1169  
The best conditions for strain CHP1169 PDE7A in the git3 deletion background is to pre-grow the stain in 
EMM with 2.5 mM of cAMP and by using 1x105 cells/ml as the final cell density in 5FOA. Results showed 
an OD600 of 0.93 +/- 0.05 in wells where cAMP was added to the cultures, and an OD600 of 0.07 +/- 0.01 in 
wells where cAMP was not added. 
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Figure 7.  
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Figure 8. Test different PDE7 genetic background  
 Strain CHP1189 behaves much better than strain CHP1169. Strain CHP1169 expressing PDE7A in a git3 
deletion background and the strain CHP1189 were pre-grown in EMM medium containing 2.5 mM cAMP, 
then transferred to 5FOA medium with 5mM of cAMP (positives = orange bars) or the absence of cAMP 
(negatives = brown bars). OD600 measurements were taken after 48 h of incubation at 30ºC. In strain 
CHP1169, the OD600 of the cultures +cAMP was 1.45 +/- 0.074, while the OD600 of the cultures –cAMP 
was 0.61+/- 0.05. In strain CHP1189 the OD600 of the cultures +cAMP was 1.31 +/- 0.03 and the OD600 of 
the –cAMP cultures was 0.060+/- 0.01. The Z factors for these screens were 0.65 and 0.91, respectively. 
1X=1*105, 2X=1.5*105 final cell densities added to 5FOA medium.  
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Figure 8. 
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From these data, I identified the best genetic background for which PDE7A activity was able 
to show the 5-FOA growth sensitive phenotype. By testing strain CHP1189, a PDE7A in a 
gpa2 deletion background, and, CHP1169 a PDE7A in a git3 deletion background, I found 
that strain CHP1189 behaves much better than strain CHP1169 even though both confer the 
5FOA sensitive phenotype, and had a Z factor above 0.5. Since loss of gpa2 creates a greater 
defect in cAMP than the loss of git3, it displayed less background growth, represented by the 
negative values. Based on these results, I decided to use CHP1189 for high throughput 
screening.  
 
3.3. Strain expressing PDE7A responds partially to IBMX but not to rolipram  
Before performing high throughput screening, I wanted to further test the strains against 
commercially available drugs to validate the use of CHP1189 for screening. Thus, I tested the 
effects of a known PDE4 inhibitor (rolipram), and the nonselective PDE inhibitor (IBMX) on 
the expression of the fbp1-lacZ fusion in the human PDE7A expressing strain. As seen in 
Figure 9, rolipram did not reduce β-galactosidase activity, while IBMX partially reduces  β-
galactosidase activity expressed from the PDE7A strain (35 % reduction). These results 
support results reported from previous studies indicating that PDE7 is sensitive to the 
nonselective PDE inhibitor IBMX and resistant to rolipram a PDE4 selective drug. 
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Figure 9. The PDE7A is partially sensitive IBMX and resistant to rolipram 
The PDE7 strain CHP1189 is sensitive to the nonselective PDE inhibitor IBMX and resistant to rolipram, a 
PDE4 selective drug. Rolipram did not reduce β-galactosidase activity in strain CHP1189. Whereas, the 
nonselective PDE inhibitor IBMX reduces β-galactosidase activity expressed from the PDE7A strain 
partially (35 % reduction).  
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Figure 9. 
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3.4. Screening and Hits analysis  
Using CHP1189 (5FOAs strain expressing PDE7A), I screened for compounds that would 
inhibit PDE7A to confer 5FOAR growth. By performing five major experiments 
(1091.0126, 1091.0127, 1091.0128, 1091.0129, 1091.0130), I was able to screen all of 
the available libraries at the Broad Institute (Bioactive, PK04, Analyticon, Forma, 
Natural extracts, and Commercials compounds). All available libraries at that time 
represent screening of almost 50,000 compounds. Figure10A displays the results from 
these screens. In the Figure, yellow circles represent the positive controls (cells +cAMP) 
which show high Z scores as expected; Red circles represent the negative control (cells 
+DMSO) which display low Z scores; while the purple circles represent the 50,000 
compounds that were screened. Also note the diagonal distribution of spots, which 
represents high data reproducibility of the screens, which were performed in duplicates.  
 
Duplicate plates were screened and compounds that confer such growth with composite Z 
scores of ≥8.53 were identified as “Hits” which comprised almost 750 compounds 
(Figure 10B). Most of the hits that were identified were from the commercial libraries 
representing 40 % of the total hits (Figure 11).   
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Figure 10. PDE7A screening results  
(A) Display of the results from the screen, yellow circles represent the positive controls (cells +cAMP) 
which show high Z scores as expected; Red circles represent the negative control (cells +DMSO) which 
display low Z scores, while the purple circles represent the all compounds that were screened.  
(B) Compounds that confer such growth with composite Z scores of ≥8.53 were identified as “Hits” which 
comprised almost 750 compounds. 
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Figure10. 
A. 
 
 
 
 
 
 
 
 
 
 
B. 
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Figure 11. Most of PDE7A hits were identified from the commercial libraries 
Most of the 750 hits that were identified were from the commercial libraries (experiment number 
1091.0129-purple and 1091.0130-green) representing 40% of the total hits. 
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Figure 11. 
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1091.0128 Analyticon+Forma+Natural Extracts
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1091.013 Commercials 2
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These results were then compared with those from screens against other PDEs (PDE2A, 
PDE4A, PDE4B, and Cgs2) to identify PDE7A-specific inhibitors. This comparison 
resulted in 20 specific compounds with composite Z scores of ≥ 44.5, identified as 
“PDE7A specific Hits” (Figures 12). Four of these specific hits were picked for further 
analysis (compounds 11, 12, 13, 14).  
 
3.5. PDE7A specific inhibitors restore 5FOAR growth  
I performed additional 5FOA assays to confirm “PDE7A specific hits”, and to identify 
the ED50 (The dose of a compound that is pharmacologically effective to stimulate 
growth to 50% of the OD of a saturated  culture ) of compound (11, 12, 13, 14, 15, PAN). 
Compound 15 = BRL 50481, is the only specific PDE7 inhibitor commercially available 
whereas, PAN is a compound that stimulates  the growth of  most of the PDE-expressing 
strains. Compound number 15 and PAN were used as controls to validate our assays. 
Cells were subjected to 18 serially-diluted concentrations of each drug starting from 
500mM and ending with 0.5 mM(2/3 serial dilutions).  
 
In the presence of PDE7A inhibitors, cells should restore 5FOAR growth by elevating 
cAMP levels to repress fbp1-ura4 transcription. As seen in (Figures 13, 14) compound 
11, 12, 14, 15, and PAN, all except drug 13, significantly exhibit compound -dependent 
growth. PDE7A was inhibited by less than 10 mM of compound 11, and 14.  
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Figure 12.  PDE7 specific inhibitors 
 The 750 hits were compared with other PDE (PDE2A, PDE4A, PDE4B, and Cgs2) hits to identify PDE7A 
specific inhibitors. This resulted in 20 specific compounds with composite Z scores of ≥ 44.5, identified as 
“PDE7A specific Hits”. Four of these specific hits were picked for further analysis (compound #11, #12, 
#13, #14).  
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Figure 12. 
 
 
 
 
 
Expt Num Comp Lab Num PlateName Well Raw ValueA Raw ValueB ZScoreA ZScoreB Reproducibility Composite Z
1091.0129 14 2005 B21 0.835 0.734 123.92 103.24 0.9959 160.6258
1091.0126 ND 2158 O06 1.144 1.145 93.86 82.88 0.9981 124.9724
1091.0127 ND 2181 N05 1.196 1.152 89.28 70.52 0.9932 112.997
1091.0128 ND 2055 G05 0.937 0.924 82.73 78.87 0.9997 114.2724
1091.0128 ND 2058 I14 0.845 0.785 74.17 66.11 0.9984 99.1982
1091.0129 12 2009 A18 0.556 0.498 79.81 67.29 0.9964 104.0182
1091.0126 ND 2159 B09 0.81 0.938 65.04 67.19 0.9999 93.4985
1091.0126 11 2160 G10 0.83 0.812 67.19 57.6 0.9971 88.2396
1091.0128 ND 2002 D09 0.684 0.64 58.41 52.63 0.9987 78.5153
1091.0128 ND 2057 G05 0.646 0.666 55.38 55.36 1 78.3038
1091.013 ND 2071 P12 0.442 0.493 46.97 57.56 0.9949 73.9171
1091.013 ND 2044 D16 0.417 0.38 43.96 42.75 0.9999 61.31
1091.0127 ND 2281 O07 0.653 0.65 46.17 37.78 0.995 59.3637
1091.013 ND 2073 D15 0.366 0.332 37.99 36.38 0.9998 52.5913
1091.013 ND 2074 J08 0.353 0.356 36.15 39.69 0.9989 53.6276
1091.013 13 2064 J21 0.326 0.381 32.88 42.64 0.9918 53.406
1091.0128 ND 2070 N01 0.435 0.431 33.54 32.93 1 47.0062
1091.0127 ND 2094 F23 0.495 0.521 34.06 29.63 0.9976 45.0371
1091.0127 ND 2093 B11 0.498 0.502 34.07 28.23 0.9956 44.0504
1091.0128 ND 2070 G18 0.491 0.338 38.86 24.35 0.9747 44.6967
14           
  
 
 
12      
 
 
 
              
11  
    
 
 13           
 1091.0126 Bioactives1091.0127 PK041091.0128 Analyticon+Forma+Natural Extracts
1091.0129 Commercials 1
1091.013 Commercials 2
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Figure 13. PDE7A specific inhibitors restore 5FOAR growth 
In the presence of PDE7A inhibitors, cells should restore 5FOAR growth by elevating cAMP levels to 
repress fbp1-ura4 transcription. Drugs 11, 12, 14, 15, and PAN (the exception is drug 13) significantly 
exhibit drug dependent –growth.  
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Figure 13.  
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Figure 14. Comparing PDE7A specific inhibitors effect in 5FOA medium 
Compound 11, 14 and 12 are potential PDE7 inhibitors. By comparing the compounds with each other, 
PDE7A was inhibited by < 10 mM of compound 11, and 14, whereas compound 12 and 15 inhibited 
PDE7A in a much lower concentration showing 3.9 and 1.5 ED50s, respectively. Compound 13 did not 
inhibit PDE7. 
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Figure 14. 
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3.6. PDE 7A specific inhibitor elevate cAMP levels   
To determine if the effect of drugs 11, 12, 13, 14 and 15 is through PDE7A inhibition, I 
measured cAMP levels before and after drug treatment. As shown in Figure 15, cAMP 
levels increase within 1 h of exposure to 100 mM inhibitor in response to drug 11, 14, 15, 
and 13. Interestingly, drug 13 shows an increase in cAMP level even though showed the 
least stimulation of 5FOAR growth. Drug 12 did not show significant increase in cAMP 
levels (See Summary and Discussion). 
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Figure 15. Comparing PDE7A specific inhibitors effect on cAMP levels  
PDE 7A specific inhibitor elevates cAMP levels. cAMP levels were measured before (blue bars) and after 
(red bars) the compound treatment. cAMP levels increase in response to drugs 11, 14, 15, and 13, but, drug 
12 did not show significant increase in cAMP levels.  
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Figure 15. 
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Compound 12 and 15 inhibited PDE7A in a much lower concentration showing 3.9 and 
1.5 ED50s, respectively (See Discussion). 
 
CONCLUSION  
4.1. Summary  
I have integrated human PDE7A into the S. pombe genome and identified a strain for use 
in a cell-based screening platform for finding PDE7A inhibitors. Using strain CHP1189, I 
have successfully screened 50,000 compounds and detected novel PDE7A inhibitors. 
High throughput screens performed against compound libraries identified almost 750 
compounds that promote 5FOAR growth. Comparing the results with other PDE hits from 
our lab identified at least 20 specific inhibitors with high Z scores.   
 
The recently identified PDE7A specific inhibitor (BRL 50481) (LERNER and EPSTEIN 
2006; SMITH et al. 2004) promotes PDE7A-expressed cells 5FOAR growth and shows 
remarkable increases in cAMP levels upon cell treatment, supporting the validity of our 
assay and our hits.   
 
Compound 11 and 14 were highly effective against PDE7A on cAMP and confer 5FOAR 
growth. On the other hand, compound 13 promotes 5FOAR growth poorly, but elevated 
cAMP level in 1 h of exposure. These data may suggest that compound 13 is less stable 
than other drugs, since we don’t see any growth effect after 48 h of incubation. Therefore, 
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it is possible that drug 13 cannot maintain PDE7A inhibition for a long time, while we 
still can observe its effect on cAMP in 1 h after treatment. Another interesting finding is 
that a low dose of drug 12 was enough to confer 5FOAR, but growth plateaus at 6 µM of 
drug and display no elevated cAMP levels after 1 h of drug treatment.  
 
4.2. Future directions  
Results from this study suggest that compound 12 might function differently when 
inhibiting PDE7A. One reason for not seeing an effect on cAMP levels is that 1 h of 
exposure was not enough for drug 12 to inhibit PDE7A. Thus, it would be interesting to 
do a cAMP and 5FOA assay in a time course manner to determine when the cells plateau, 
and investigate if more than 1 h of treatment can increase cAMP levels. These 
experiments may uncover the mechanism of how drug 12 inhibits PDE7A. In addition, 
testing more drugs out of the “PDE7A specific collection” will help us understand the 
mode of action of these drugs, especially since some of the drugs share structural 
similarity (data not shown). 
 
Little is known about PDE7 function and tools such as these inhibitors could help in the 
characterization of PDE7. Smith et al 2004 found that BRL 50481(SMITH et al. 2004) 
was able to block TNF secretion in a dose-dependent manner in aged monocytes and was 
more efficient when combined with the PDE4 inhibitor rolipram. In addition, T-2585 a 
dual PDE4/PDE7 inhibitor that suppresses the proliferation of T cells was more effective 
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than RP 73401 (piclamilast) a PDE4 selective inhibitor (LERNER and EPSTEIN 2006; 
SMITH et al. 2004). Therefore, finding and testing an inhibitor from our libraries that can 
target PDE7 and PDE4 can possibly be more effective as an anti-inflammatory drug.  
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APPENDIX TWO 
SCREENING FOR HUMAN PDE7A ACTIVATORS USING 
A YEAST CELL-BASED SYSTEM 
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SCREENING FOR HUMAN PDE7A ACTIVATORS USING A YEAST CELL-
BASED SYSTEM 
 
1. INTRODUCTION  
Finding new PDE7A activators can advance our understanding of the function of that 
enzyme. Thus it can potentially improve basic research and therapeutic approaches. I will 
describe herein an in vivo screen for identifying chemical activators of PDE7A using the 
same assay platform utilized for finding PDE7A inhibitors (APPENDIX I).  
 
A potential PDE activator should confer growth in SC-ura or EMM medium to a strain 
that expresses high cAMP levels by reducing its cAMP levels, which will allow fbp1-
ura4 transcription. A suitable strain for screening must fail to grow in a SC- Ura /EMM-
Ura medium in the absence of PDE7A stimulation.   
 
2. SCREENING PROCESS  
High throughput drug screens were performed at the Broad Institute’s Chemical Biology 
Program screening facility. PDE7A cultures (CHP1171) were pre-grown in EMM 
complete medium overnight. Cells were then washed, mixed very well and transferred to 
384-well microtiter dishes into EMM-Ura or SC-ura medium at a final density 1.5 x105 
cells/ml and a final volume of 50 ml. 100 nl of compounds were pinned into the wells at a 
final concentration of 20 mM. Control plates received 100 nl DMSO. Cultures were 
incubated for 48 h at 30ºC, sealed in a container with moist paper towels to prevent 
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evaporation. Optical density (OD600) of cultures was measured after mixing the cells with 
a plate mixer.  
 
 
 
3. RESULTS  
 
3.1. Strain optimization 
To determine the best conditions for high throughput for chemical PDE7A activator 
screening, I used a PDE7A-strain that has an fbp1-ura4 reporter that expresses high 
cAMP levels. This strain should not grow in SC- Ura /EMM-Ura medium in the absence 
of a PDE7A activator. Therefore, I performed an optimization experiment to determine 
the appropriate optimal cell densities that give low coefficient of variation (CV) value 
(The cut-off used by the Broad Institute’s Chemical Biology Program requires a ≤15 % 
value). This is needed for screens for screens for which a positive control is not available 
as seen in Figure 1 by using 1.5x105 cell density, I was able to lower the CV values using 
SC- Ura /EMM-Ura.  
 
3.2. Strain Screening and Hit’s  
Using CHP1171, a strain expressing human PDE7A which express high basal cAMP 
levels, I screened for compounds that if activated, PDE7A should confer Ura+ growth due 
to repression of fbp1-ura4 expression. By performing two experiments (1091.0133) and 
(1091.0134) I screened the Bioactive, Natural extracts libraries and some additional 
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plates from Analyticon library. Experiment number (1091.0133) was performed in EMM 
-ura while screen number (1091.0134) was performed in SC -ura. Both experiments were 
incubated for 48 h. I also read experiment (1091.0134) plates after 67 h of incubation, 
and renamed the experiment number (changed to 1091.0135). Duplicate plates were 
screened and compounds that confer such growth with composite Z scores of ≥8.53 were 
identified as “Hits”. One general finding in all of the activator screens is the presence of 
spots scattering away from the diagonal direction creating an “L” shape. This was due to 
problems with the reproducibility of the replicates. 
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Figure 1. Optimization of strain CHP1171  
Optimization experiment of strain CHP1171 to determine the right cell densities that give lower coefficient 
of variation (CV) values (The cut-off used by the Broad Institute’s Chemical Biology Program requires a 
≤15 % value). Using 1.5x105 cell densities gave the lowest the CV values using SC- Ura /EMM-Ura. 
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Figure 1. 
 
 
 
 
 
 
 
 
1x=0.5*10
5
2x=1*10
5
3x=1.5*10
5
EMM-ura1x EMM-ura1x
avg 0.04311719 avg 0.04141146
stdev 0.01791278 stdev 0.0162791
CV 41.544402 CV 39.3106177
EMM-ura2x EMM-ura2x avg 0.04595182
avg 0.0506276 stdev 0.006449
stdev 0.01655371 CV 14.0342623
CV 32.6970106
EMM-ura3x EMM-ura3x
avg 0.06648307 avg 0.05430339
stdev 0.01416313 stdev 0.00600003
CV 21.3033617 CV 11.0490972
Sc-ura1x avg 0.04129557 Sc-ura1x avg 0.04057943
stdev 0.01047079 stdev 0.00637989
CV 25.3557183 CV 15.7219706
Sc-ura2x Sc-ura2x
avg 0.0459349 avg 0.04480208
stdev 0.01121758 stdev 0.01062898
CV 24.4206048 CV 23.7242884
Sc-ura3x Sc-ura3x
avg 0.05585286 avg 0.05167448
stdev 0.01415367 stdev 0.00490837
CV 25.3409958 CV 9.49863009
 199 
3.2.1. Experiment 1091.0133 Hits 
Using CHP1171, a strain expressing human PDE7A for screening in EMM-Ura, I only 
obtained two hits from the Natural extract library, which were highly reproducible with a 
composite Z of 11 and 10.5, respectively, as seen in Figure 2.  
 
3.2.2. Experiment 1091.0134 Hits 
Using CHP1171, a strain expressing human PDE7A for screening in SC –Ura , I obtained 
15 hits (Figure 3 A, B), three of them were DMSO, as seen in (Figure 3C) highlighted in 
gray. The plates of this experiment were read again after 67 h and renamed to experiment 
1091.0135. Results from these experiments are shown in (Figure 4) were it is displayed 
shared hits between PDE7A and PDE8 and PDE2 (See Discussion).  
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Figure 2. Experiment 1091.0133 Hits 
CHP1171 growth in EMM-Ura displayed only two hits, which were reproducible with a composite Z 11, 
and 10.5. Note the presence of spots scattering away from the diagonal direction creating an “L” shape due 
to low reproducibility of replicates. Red circles represent the negative control (cells+DMSO), while the 
blue circles represent compounds that were screened.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 201 
Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plate Type Well ZScoreA ZScoreB CompositeZ Reproducibility Compound Name 
2091 Cpd D19 7.1 8.6 11.1002 0.9955 LDV0794.217I.Frx2(5) 
2144 Cpd K04 6.1 8.78 10.5235 0.9842 86.3983V.35 
 
 
Cpd 
Neg 
 
> 8.5 
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Figure 3. Experiment 1091.0134 Hits  
(A) Display of PDE7A screen results using CHP1171 strain in SC -Ura. (B) Display of 15 hits on the 
diagonal (green circle), although this indicates three DMSO negatives control wells (red circles highlighted 
in gray). Note the presence of spots scattering away from the diagonal direction creating an “L” shape due 
to low reproducibility of replicates. Red circles represent the negative control (cells +DMSO), while the 
blue circles represent compounds that were screened. (C) Table show 15 hits, three of them were DMSO 
highlighted in gray. 
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Figure 3. 
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(C) 
 
Plate Well ZScoreA Type ZScoreB CompositeZ Reproducibility Compound Name 
2099 C20 9.99 Cpd 15.18 17.7997 0.9795 
malachite green 
carbinol base 
2099 G17 5.63 Cpd 7.02 8.9429 0.994 thionin acetate 
2099 I05 10.06 Cpd 9.66 13.9448 0.9998 mitoxantrone 
2104 H08 14.01 Cpd 6 14.1506 0.9284 
3,4-
Dichloroisocoumarin 
2160 F18 7.98 Cpd 9.84 12.604 0.9946 
mitoxanthrone 
hydrochloride 
2160 K03 11.9 Cpd 8.03 14.0906 0.9816 menthone 
2160 L14 16.33 Cpd 9.31 18.1308 0.9645 tropicamide 
2161 I18 8.33 Cpd 11.2 13.8141 0.9894 gentian violet 
2162 L02 7.79 Con 8.39 11.4427 0.9993 DMSO 
2163 K12 9.35 Cpd 6.02 10.8686 0.9774 isobutylmethylxanthine 
2163 P05 13.13 Cpd 8.37 15.2029 0.9763 4-nonylphenol 
2165 B08 10.14 Cpd 4.64 10.448 0.9372 Azathymine, 6 
2166 H04 6.75 Cpd 8.39 10.708 0.9942 Butacaine 
Base K05 5.35 Con 6.82 8.6049 0.9928 DMSO  
Base L10 7.92 Con 7.8 11.1151 1 DMSO  
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Figure 4. Experiment 1091.0135 Hits  
The plates of experiment 1091.0134 were read again after 67 h and renamed to experiment 1091.0135. (A) 
Display PDE7A screen results using (CHP1171) strain in SC –Ura after 67 h (B) Display hits on the 
diagonal (green check mark). Note the presence of spots scattering away from the diagonal direction 
creating an “L” shape due to low reproducibility of replicates. Red circles represent the negative control 
(cells +DMSO), while the blue circles represent compounds that were screened. 
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Figure 4.  
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Table 1. Shared hits between (PDE7A, PDE8 and PDE2) 
This table demonstrates the compounds that were shared hits among activators screens 
carried out against strains expressing PDE7A, PDE8 and PDE2. Yellow: PDE7A Hits (48 
and 67 h). Green: PDE7A and PDE2 shared hits. Blue: PDE7, PDE8 and PDE2 shared 
hits. The presence of spots scattering away from the diagonal direction creating an “L” 
shape is due to low reproducibility of replicates. 
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Table 1. 
 
 
 
 
 
 
 
 
 
 
Type Plate Well ZScoreA ZScoreB CompositeZ Reproducibility Compound Name 
Cpdm 2104 E07 60.59 90.6 106.904 0.9809 Oxindole I 
Cpd 2105 L03 37.27 34.84 50.9863 0.9994 Ro-31-8425 
Cpd BioKin1 C11 41.65 29.6 50.3835 0.986 BiomolKI2_000016 
Cpd 2099 C20 14.41 21.9 25.6722 0.9794 malachite green carbinol base 
Cpd 2159 J11 13.03 22.13 24.8568 0.9681 
uridine triphosphate 
trisodium 
Cpd 2099 K06 14.69 16.69 22.1907 0.998 
N,N-dimethyl-D-erythro-
sphingosine 
Cpd 2104 H08 20.77 9.33 21.2855 0.9347 3,4-Dichloroisocoumarin 
Cpd 2099 I05 14.69 15.12 21.0774 0.9999 mitoxantrone 
Cpd 2161 I18 12.26 17.23 20.8522 0.9861 gentian violet 
Cpd 2160 F18 11.87 15.52 19.3698 0.9912 mitoxanthrone hydrochloride 
Cpd 2160 K03 16.14 9.22 17.9328 0.9648 menthone 
Cpd 2163 E20 14.26 9.29 16.649 0.9784 6-aminonicotinamide 
Cpd 2160 L14 11.49 11.89 16.5325 0.9999 tropicamide 
Cpd 2099 G06 10.99 11.48 15.8939 0.9998 
N,N,N-trimethyl-D-erythro-
sphingosine 
Cpd 2099 L13 11.18 10.88 15.5998 0.9999 
D-lactosyl-B1-1'-D-erythro-
sphingosine 
Cpdweak 2099 G17 8.62 10.27 13.3617 0.9962 thionin acetate 
Cpd 2163 K12 11.13 7.23 12.9811 0.9781 isobutylmethylxanthine 
Con Base L10 10.16 7.7 12.6346 0.9906 DMSO  
Con 2162 L02 7.69 9.84 12.3963 0.9925 DMSO  
Cpdm 2165 B08 11.24 4.91 11.4229 0.9312 Azathymine, 6 
Cpdm 2166 H04 7.37 8.65 11.3345 0.9968 Butacaine 
Cpd 2105 G02 9.68 3.71 9.4705 0.9133 Sphingosylphosphorylcholine 
Cpd 2165 F11 5.93 6.73 8.9539 0.998 
Chicago sky blue 6B;4-
aminoantipyrine 
Con Base K05 4 8.31 8.7058 0.9439 DMSO  
Con 2160 G01 8.18 3.89 8.534 0.9424 DMSO  
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DISCUSSION  
One challenge of doing this type of screen is problems with the reproducibility of 
replicates (including the DMSO, which in some cases were showing up as positives in 
one of the two replicates). Comparing this screen with other screens performed on 
PDE2A and PDE8 in EMM-Ura (Wang, Demirbas) all three screens identified compound 
2099 C20 (malachite green carbinol base) as a modest hit. Whereas, PDE7A screens 
carried in SC-ura compared with PDE2A screen have 8 shared hits. Therefore, despite the 
reproducibility problem encountered doing this screen, finding shared suggest that the 
growth is not due to PDE stimulation.  
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OPTIMIZATION OF DIFFERENT STRAINS TO BE USED FOR HIGH 
THROUGHPUT SCREENING 
 
1. INTRODUCTION  
To determine the best conditions for high throughput drug screening, a number of factors 
need to be taken into consideration including the right genetic background, the right 
cAMP concentration for pre-growth conditions, and final cell densities, all important 
elements in the optimization process. Here, I will show the best cell densities that should 
be used for four strains CHP1156, CHP1156, CHP1132 and CHP1142 to perform high 
throughput screening, as shown in Table 1.  
 
2. STRAIN OPTIMIZATION 
2.1.  Strain CHP1156 optimization  
Strain CHP1156 expressing Trypanosoma cruzi PDE in git3 deletion background was 
pre-grown in EMM medium containing concentration 5 mM of cAMP and different final 
cell densities (2x105, 2.5 x105) then cultures were transferred to 5FOA in the presence or 
absence 5mM cAMP. All plates received 100 nl DMSO. The OD600 measurements were 
taken after 48 h of incubation at 30ºC. Cells were grown in the presence of cAMP in 
order to repress the fbp1-ura4 reporter prior to exposure to 5FOA medium. I found that 
the best cell densities for this strain was 2.5 x105 as final cell density when transferred to 
5FOA (Figure 1).  
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2.2. Strain CHP1155 optimization  
Strain CHP1155 expressing PDE4A in the gpa2 deletion background was pre-grown in 
EMM medium containing 2.5 mM of cAMP and different final cell densities (0.75x105, 
1x105) then cultures were transferred to 5FOA in the presence or absence 5 mM cAMP. 
Rolipram was also used as positive control for this strain. All plates received of 100 nl 
DMSO. OD600 measurements were taken after 48 h of incubation at 30ºC. Cells were 
grown in the presence of cAMP in order to repress the fbp1-ura4 reporter prior to 
exposure to 5FOA medium. I found that the best cell density for this strain was 1 x105 as 
the final cell density when transferred to 5FOA (Figure 2). 
 
2.3. Strain CHP1132 and CHP1142 optimization 
Strain CHP1132 and CHP1142 were expressing S. pombe cgs2 in a git32 deletion 
background with different mating types h- and an h+, respectively. Both were pre-grown 
in EMM medium containing 2.5 mM of cAMP and different final cell densities (1.5x105, 
2x105 cells/ml) then cultures were transferred to 5FOA in the presence or absence 5 mM 
cAMP. All plates received 100 nl of DMSO. OD600 measurements were taken after 48 h 
of incubation at 30ºC. Cells were grown in the presence of cAMP in order to repress the 
fbp1-ura4 reporter prior to exposure to 5FOA medium. I found that the best cell density 
for both strains is 1.5 x105 cells/ml as the final cell density when transferred to 5FOA 
(Figure 1).   
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3. CONCLUSION 
All of these strains are ready to go through high throughput screening (HTS) since I 
was able to obtain a Z factor higher than 0.5.  
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Figure 1. Strains optimizations with 1x cell density  
Two experiments were performed on different days on strains CHP1132, CHP1142, CHP1155, CHP1156 
using these cells densities 1x=1.5x105, 1.5 x105, 0.75 x105, 2x105 cells/ml respectively. Z factors of all the 
strains were higher than the Broad institute cut off. 
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Figure 1.  
 
 
 
 
 
 
 
 
 
 
First experiment Second experiment 
CHP 1132 POS NEG Z CHP 1132 POS NEG Z
avg 1.21 0.07 0.92 avg 0.79 0.1 0.81
stdev 0.02 0.01 stdev 0.04 0.01
CV 1.84 10.1 CV 4.69 6.29
CHP1142 POS NEG Z CHP1142 POS NEG Z
avg 1.25 0.09 0.9 avg 1.07 0.1 0.81
stdev 0.03 0 stdev 0.05 0.01
CV 2.8 4.99 CV 4.89 7.52
CHP 1155 POS NEG Z CHP 1155 POS NEG Z
avg 1.27 0.05 0.88 avg 1.21 0.05 0.9
stdev 0.04 0.01 stdev 0.04 0
CV 3.37 14.6 CV 3.04 6.63
CHP 1155 RolipramPOS NEG Z CHP 1155 Rolipram POS NEG Z
avg 0.86 0.05 0.56 avg 1.07 0.05 0.67
stdev 0.11 0.01 stdev 0.11 0
CV 13.1 12.9 CV 10.2 6.38
CHP 1156 POS NEG Z CHP 1156 POS NEG Z
avg 1.27 0.1 0.86 avg 1.06 0.35 0.6
stdev 0.03 0.02 stdev 0.06 0.04
CV 2.74 18.9 CV 5.33 11.4
CHP 1169 POS NEG Z CHP 1169 POS NEG Z
avg 1.52 0.78 0.58 avg 1.39 0.44 0.71
stdev 0.04 0.06 stdev 0.05 0.04
CV 2.91 7.66 CV 3.29 9.97
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Figure 2. Strain optimizations with 2X cell density  
Two experiments were performed on different days using higher cell densities than shown in Figure 1 on 
strains CHP1132, CHP1142, CHP1155, CHP1156. Cell densities used for theses strains were 2X= 2x105, 2 
x105, 1x105, 2.5 x105, respectively. Z factors of all strains under these conditions were also higher than the 
Broad Institute cut off. 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
First experiment Second experiment 
CHP 1132 POS NEG Z CHP 1132 POS NEG Z
avg 1.21 0.07 0.92 avg 0.79 0.1 0.81
stdev 0.02 0.01 stdev 0.04 0.01
CV 1.84 10.1 CV 4.69 6.29
CHP1142 POS NEG Z CHP1142 POS NEG Z
avg 1.25 0.09 0.9 avg 1.07 0.1 0.81
stdev 0.03 0 stdev 0.05 0.01
CV 2.8 4.99 CV 4.89 7.52
CHP 1155 POS NEG Z CHP 1155 POS NEG Z
avg 1.27 0.05 0.88 avg 1.21 0.05 0.9
stdev 0.04 0.01 stdev 0.04 0
CV 3.37 14.6 CV 3.04 6.63
CHP 1155 RolipramPOS NEG Z CHP 1155 Rolipram POS NEG Z
avg 0.86 0.05 0.56 avg 1.07 0.05 0.67
stdev 0.11 0.01 stdev 0.11 0
CV 13.1 12.9 CV 10.2 6.38
CHP 1156 POS NEG Z CHP 1156 POS NEG Z
avg 1.27 0.1 0.86 avg 1.06 0.35 0.6
stdev 0.03 0.02 stdev 0.06 0.04
CV 2.74 18.9 CV 5.33 11.4
CHP 1169 POS NEG Z CHP 1169 POS NEG Z
avg 1.52 0.78 0.58 avg 1.39 0.44 0.71
stdev 0.04 0.06 stdev 0.05 0.04
CV 2.91 7.66 CV 3.29 9.97
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